0001663577-23-000137.txt : 20230330 0001663577-23-000137.hdr.sgml : 20230330 20230329190554 ACCESSION NUMBER: 0001663577-23-000137 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230330 DATE AS OF CHANGE: 20230329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SKINVISIBLE, INC. CENTRAL INDEX KEY: 0001085277 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880344219 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-25911 FILM NUMBER: 23776718 BUSINESS ADDRESS: STREET 1: 6320 S SANDHILL ROAD STREET 2: SUITE 10 CITY: LAS VEGAS STATE: NV ZIP: 89120 BUSINESS PHONE: 7024337154 MAIL ADDRESS: STREET 1: 6320 S SANDHILL ROAD STREET 2: SUITE 10 CITY: LAS VEGAS STATE: NV ZIP: 89120 FORMER COMPANY: FORMER CONFORMED NAME: SKINVISIBLE INC DATE OF NAME CHANGE: 19990428 10-K 1 skvi10k123122.htm
0001085277 false --12-31 2022 FY 0001085277 2022-01-01 2022-12-31 0001085277 2022-06-30 0001085277 2023-03-31 0001085277 2022-12-31 0001085277 2021-12-31 0001085277 2021-01-01 2021-12-31 0001085277 us-gaap:CommonStockMember 2020-12-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001085277 SKVI:StockPayableMember 2020-12-31 0001085277 us-gaap:RetainedEarningsMember 2020-12-31 0001085277 2020-12-31 0001085277 us-gaap:CommonStockMember 2021-12-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001085277 SKVI:StockPayableMember 2021-12-31 0001085277 us-gaap:RetainedEarningsMember 2021-12-31 0001085277 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001085277 SKVI:StockPayableMember 2021-01-01 2021-12-31 0001085277 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001085277 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001085277 SKVI:StockPayableMember 2022-01-01 2022-12-31 0001085277 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001085277 us-gaap:CommonStockMember 2022-12-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001085277 SKVI:StockPayableMember 2022-12-31 0001085277 us-gaap:RetainedEarningsMember 2022-12-31 0001085277 1999-06-06 2022-12-31 0001085277 SKVI:ConvertibleNotesMember 2022-01-01 2022-12-31 0001085277 2019-06-30 0001085277 2019-01-01 2019-06-30 0001085277 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-06-30 0001085277 SKVI:ConvertibleNotesRelatedPartyMember 2022-01-01 2022-12-31 0001085277 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-12-31 0001085277 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-12-31 0001085277 SKVI:TwoOfficersMember 2022-01-01 2022-12-31 0001085277 SKVI:TwoOfficersMember 2021-01-01 2021-12-31 0001085277 SKVI:RelatedPartyNotesPayableOneMember 2022-12-31 0001085277 SKVI:RelatedPartyNotesPayableOneMember 2021-12-31 0001085277 SKVI:NineteenNotesPayableMember 2018-12-31 0001085277 SKVI:NineteenNotesPayableMember 2013-05-22 2018-12-31 0001085277 SKVI:PastDueMember 2022-12-31 0001085277 SKVI:ConvertibleNoteOneMember 2022-12-31 0001085277 SKVI:ConvertibleNote1Member 2022-12-31 0001085277 SKVI:ConvertibleNote1Member 2021-12-31 0001085277 SKVI:ConvertibleNoteSixMember 2019-12-31 0001085277 SKVI:ConvertibleNote6Member 2019-10-01 2019-12-31 0001085277 SKVI:ConvertibleNote6Member 2022-01-01 2022-12-31 0001085277 SKVI:ConvertibleNote6Member 2021-01-01 2021-12-31 0001085277 SKVI:ConvertibleNote6Member 2022-12-31 0001085277 SKVI:ConvertibleNote6Member 2021-12-31 0001085277 SKVI:TotalConvertibleNotesMember 2022-12-31 0001085277 SKVI:TotalConvertibleNotesMember 2021-12-31 0001085277 SKVI:TotalConvertibleNotesCurrentMember 2022-12-31 0001085277 SKVI:TotalConvertibleNotesCurrentMember 2021-12-31 0001085277 SKVI:TotalLongTermConvertibleNotesCurrentMember 2022-12-31 0001085277 SKVI:TotalLongTermConvertibleNotesCurrentMember 2021-12-31 0001085277 2019-10-01 2019-10-17 0001085277 2020-01-18 2021-12-31 0001085277 2020-06-01 2020-06-10 0001085277 SKVI:ExcercisePriceOneMember 2021-12-31 0001085277 SKVI:OptionExerciseMember 2022-01-01 2022-12-31 0001085277 SKVI:OptionCancelledWeightedAverageMember 2022-01-01 2022-12-31 0001085277 SKVI:ExcercisePriceTwoMember 2021-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

 

Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
   
  For the fiscal year ended December 31, 2022
   
Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934
   
  For the transition period from _________ to ________
  Commission file number: 000-25911

 

Skinvisible, Inc.
(Exact name of registrant as specified in its charter)
Nevada 88-0344219

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)
6320 South Sandhill Road, Suite 10, Las Vegas, NV 89120
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number: 702.433.7154

 

 

 
Securities registered under Section 12(b) of the Exchange Act:

 

Title of each class Name of each exchange on which registered
None not applicable

 

Securities registered under Section 12(g) of the Exchange Act:

 

Title of each class
Common Stock, par value $0.001
     

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ ] No [X]

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [ ] No [X]

 

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.

 

☐   Large accelerated filer ☐   Accelerated filer
  Non-accelerated Filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of

the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. [ ]

 

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter $551,261.

 

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. 4,593,843 common shares as of March 31, 2023

 

  

 

TABLE OF CONTENTS

 

    Page 

PART I

 

Item 1. Business 3
Item 1A. Risk Factors 6
Item 2. Properties 13
Item 3. Legal Proceedings 13
Item 4. Mine Safety Disclosures 13

 

PART II

 

Item 5. Market for Registrant’s Common Equity and Related Stockholder Matters and Issuer Purchases of Equity Securities 14
Item 6. Selected Financial Data 16
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 16
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 19
Item 8. Financial Statements and Supplementary Data 19
Item 9. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure 20
Item 9A. Controls and Procedures 20
Item 9B. Other Information 20
Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 20

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance 21
Item 11. Executive Compensation 23
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 24
Item 13. Certain Relationships and Related Transactions, and Director Independence 25
Item 14. Principal Accountant Fees and Services 25

 

PART IV

 

Item 15. Exhibits, Financial Statement Schedules 26
Item 16. Form 10-K Summary 26

 2 

 

PART I

 

Item 1. Business

 

Company Overview

 

We, through our wholly owned subsidiary Skinvisible Pharmaceuticals Inc., are a pharmaceutical research and development (“R&D”) company that has developed and patented an innovative polymer delivery system, Invisicare® and formulated over forty topical skin products, which we out-license globally. We were incorporated in 1998, and target an estimated $80 billion global skincare and dermatology market and a $30 billion global over-the-counter market as well as other healthcare / medical and consumer goods markets.

 

With the research and development complete on forty products and numerous patents issued (technology and product patents), we are ready to monetize our investment. Our business model will continue to be to out-license our patented prescription and over-the-counter (“OTC”) products featuring Invisicare to established manufacturers and marketers of brands internationally and to maximize profits from the products we have already out-licensed.

 

 

The opportunity for us to license our products continues to be a viable model as the need for pharmaceutical companies to access external R&D companies for new products due to their own down-sizing or elimination of internal R&D departments. The demand for our products is enhanced due to the granting of key US and international patents and the completed development of a number of unique products.

 

  

Our Flagship Product

 

Pivotal to our success is our patented polymer delivery system technology Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a unique formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active.

  

Invisicare is specifically formulated to carry water insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents. Products utilizing Invisicare have the proven ability to bond active ingredients to the skin for up to four hours and longer. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants.

When topically applied, these formulated products adhere to the skin's outer layers, forming a protective bond, resisting wash-off, and delivering targeted levels of therapeutic or cosmetic skincare agents to the skin. They allow enhanced delivery performance for a variety of skincare agents resulting in improved efficacy, longer duration of action, reduced irritation and lower dosage of active agent required. The "invisible" polymer compositions wear off as part of the natural exfoliation process of the skin's outer layer cells.

 

The advantage of products formulated with Invisicare is (1) Invisicare’s ability to bind active ingredients (the drug) to the skin, forming a protective bond on the skin, for extended periods of time; (2) Invisicare can deliver targeted levels (high or low) of therapeutic or cosmetic ingredients to the skin in a controlled release; (3) Invisicare can help to reduce the irritation of some active ingredients due to how it controls the slower release of that active ingredient; and (4) Invisicare science proves that it provides a protective skin barrier which helps retain the natural moisture content of the skin, while still allowing it to breathe. These benefits present an excellent opportunity for clear scientific advantages and marketing messages which resonate with physicians and consumers.

 

 3 

 

We have positioned ourselves in the $80 billion worldwide prescription and over-the-counter dermatology and skincare market. We generate revenue by:

 

  • LICENSING: We develop topical prescription and over-the-counter products enhanced with Invisicare to license to pharmaceutical and consumer goods companies around the world for an upfront fee and ongoing royalties;
  • CO-DEVELOPMENT: We assist pharmaceutical clients in the early development of the most optimal formulation, which they then take forward into clinical testing;
  • LIFE CYCLE MANAGEMENT: We provide cost-effective solutions to global pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent and new product benefits and line extensions. Pharmaceutical companies are under a lot of pressure to develop innovative strategies to counteract the revenue loss from their drugs coming off patent.

License Agreement with Quoin

 

On October 17, 2019, we entered an Exclusive License Agreement with Quoin Pharmaceuticals, Inc., a Delaware corporation (“Quoin”) pursuant to which we granted to Quoin a license to certain patents for the development of products for commercial sale. In exchange for the license, Quoin agreed to pay to us a license fee of $1,000,000 (the “License Fee”) and a single digit royalty interest of all net sales on the licensed products subject to adjustment in certain situations. The agreement also requires that Quoin make certain milestone payments to us upon achieving regulatory approval milestones for certain drug products.

 

The agreement was subject to termination, if among other things, 50% of the license fee is not paid by December 31, 2019 and if the full License Fee is not paid by March 31, 2020. No payments were made by Quoin and the agreement was terminated. Both Parties subsequently determined that they continue to see the value in a partnership and therefore on May 8, 2020 and again on July 31, 2020 the companies agreed to extend the Exclusive License Agreement under the same terms to expire on December 31, 2020, and on January 27, 2021 the companies agreed to revise the milestone payments due under the agreement and to extend the agreement indefinitely.

 

On June 14, 2021, the Company entered into an amendment to change the terms of the license Fee as shown below.

 

As partial consideration for the rights conveyed by Skinvisible under this Agreement, Licensee agrees to pay to Skinvisible a one-time, non-refundable, non-creditable license issue fee of one million USD dollars (USD $1,000,000) (''License Fee''). To date, Licensee has paid one million US dollars (USD $1,000,000).

  

Additionally, the milestones in the initial agreement were changed as shown below:

 

(i)       Successful completion of Phase 2 testing: $0

(ii)      Successful completion of Phase 3 testing: $0

(iii)     Regulatory approval in either the US or EU, whichever happens first: $5,000,000

 

On June 6, 2022 we announced that Quoin has received U.S. FDA acceptance of its Investigational New Drug (IND) application for its licensed formulation which uses our Invisicare proprietary drug delivery technology. The topical formulation "QRX003" was developed to treat Nethertons Syndrome, a debilitating hereditary disorder that affects the skin, hair and the immune system. There currently is no cure or approved treatment for Netherton Syndrome.

 

With the IND approved, the clinical trial is underway. We look forward to assisting Quoin in their success and potential FDA approval as well as potentially bringing a treatment to patients suffering from Nethertons Syndrome.

 

Quoin is responsible for obtaining all FDA and other regulatory body approvals necessary to market the products in the US and other countries. Upon the successful completion of various clinical and regulatory milestones, Skinvisible is entitled to receive a milestone payment of $5 million and ongoing royalties from sales.

 

 4 

 

License Agreement with Ovation Science

 

On February 3, 2020, we entered into a License Agreement with Ovation Science Inc. pursuant to which Skinvisible granted to Ovation Science Inc. a license for the manufacture and distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay to Skinvisible a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations plus a license fee payable in year 3 of the agreement if it chooses to continue the license.

 

On June 10, 2020, Ovation Science paid us the fee otherwise due in year 3 and in exchange we extended the term of Ovation Science’s license to 6-years and granted Ovation additional rights to its hand sanitizer products and assigned Canadian Identification Numbers 02310589 and 02355558, all DermSafe Trademarks, DermSafe clinical data and the right to patent DermSafe where not currently patented. In exchange for these rights, Ovation Science paid a $100,000 license fee. We completed the required assignments during the year ending December 31, 2020 and recognized $100,000 in revenue.

 

Competition

 

Market research indicates there is reasonably limited direct competition for Invisicare and patented products in terms of performance capabilities for topically administered skin products. Many companies are seeking unique delivery systems to enhance their portfolio and purchasing companies that have delivery technology.

  

Government Regulation

 

Cosmetic and Skin Care Regulation

 

Depending upon product claims and formulation, skin care products may be regulated as cosmetics, drugs, devices, or combination cosmetics and drugs. The FDA has authority to regulate cosmetics marketed in the United States under the FDCA and the Fair Packaging and Labeling Act (“FPLA”) and implementing regulations. The Federal Trade Commission (the “FTC”) regulates the advertising of cosmetics under the FTCA.

 

The FDCA prohibits the marketing of adulterated and misbranded cosmetics. Cosmetic ingredients must also comply with the FDA’s ingredient, quality, and labeling requirements and the FTC’s requirements pertaining to truthful and non-misleading advertising. Cosmetic products and ingredients, with the exception of color additives, are not required to have FDA premarket approval. Manufacturers of cosmetics are also not required to register their establishments, file data on ingredients, or report cosmetic-related injuries to the FDA.

 

We will be responsible for substantiating the safety and product claims of the cosmetic products and ingredients before marketing. The FDA or FTC may disagree with our characterization of one or more of the skin care products as a cosmetic or the product claims. This could result in a variety of enforcement actions which could require the reformulation or relabeling of our products, the submission of information in support of the product claims or the safety and effectiveness of our products, or more punitive action, all of which could have a material adverse effect on our business. If the FDA determines we have failed to comply with applicable requirements under the FDCA or FPLA, it can impose a variety of enforcement actions from public warning letters, injunctions, consent decrees, and civil penalties to seizure of our products, total or partial shutdown of our production, and criminal prosecutions. If any of these events were to occur, it could materially adversely affect us. If the FTC determines we have failed to substantiate our claims, it can pursue a variety of actions including disgorgement of profits, injunction from further violative conduct, and consent decrees.

  

Domestic State and Local Government Regulation

 

Some states and local governments in the United States regulate the labeling, operation, sale, and distribution of our skin care products. To the extent additional state or local laws apply, we intend to comply with them.

 

 5 

 

Foreign Government Regulation

 

In general, we will need to comply with the government regulations of each individual country in which our products are to be distributed and sold. These regulations vary in complexity and can be as stringent, and on occasion even more stringent, than FDA regulations in the United States. The level of complexity and stringency is not always precisely understood today for each country, creating greater uncertainty for the international regulatory process. Furthermore, government regulations can change with little to no notice and may result in up-regulation of our product(s), thereby creating a greater regulatory burden for us. We have not yet thoroughly explored the applicable laws and regulations that we will need to comply with in foreign jurisdictions. As a result it is possible that we may not be permitted to sell our products in foreign markets or expand our business into one or more foreign jurisdictions.

 

Environmental Laws

 

We are not subject to any significant or material environmental regulation in the normal operation of our business.

 

Employees

 

Currently, we have two employees, including our CEO Terry Howlett.

 

Subsidiaries

 

We conduct our operations through our wholly-owned subsidiary, Skinvisible Pharmaceuticals, Inc.

 

Item 1A. Risk Factors

 

Risk Factors Associated with Covid 19

 

The extent to which the coronavirus (“COVID-19”) outbreak impacts our business, results of operations and financial condition will depend on future developments, which cannot be predicted.

 

The COVID-19 pandemic has caused us to modify our business practices (including employee travel, employee work locations, and cancellation of physical participation in meetings, events and conferences), and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees, customers and business partners. There is no certainty that such measures will be sufficient to mitigate the risks posed by the virus or otherwise be satisfactory to government authorities.

 

The extent to which COVID-19 impacts our business, results of operations and financial condition will depend on future developments, which are uncertain and cannot be predicted, including, but not limited to:

 

  § the duration and scope of the pandemic;

 

  § governmental, business and individual actions taken in response to the pandemic and the impact of those actions on global economic activity;

 

  § the actions taken in response to economic disruption;

 

  § the impact of business disruptions;

 

  § the increase in business failures that we may utilize as industry partners and the customers we serve;

 

  § uncertainty as to the impact or staff availability during and post the pandemic; and

 

  § our ability to provide our services, including as a result of our employees or our customers and suppliers working remotely and/or closures of offices and facilities.

 

 6 

 

Even after the coronavirus outbreak has subsided, we may continue to experience materially adverse impacts to our business as a result of its global economic impact, including any recession that has occurred or may occur in the future.

 

Risks Related to Our Financial Condition and our Business

 

We have outstanding secured and other debt that has matured and we have not paid off, which could negatively affect our ability to continue as a going concern.

 

We expect to experience high debt payments in the future as a result of our outstanding secured and unsecured liabilities. During the year ended December 31, 2021, we entered to settlement agreements to settle various notes. As part of the settlement the principal balance of the notes were settled for cash and all interest due through the date of settlement was forgiven. As of December 31, 2021, the Company has recorded a gain on settlement of the debt of $109,688 associated with the settlement of $298,400 of principal. As of December 31, 2022, $443,600 of the outstanding secured notes payable are past due and in default and have been classified as current notes payable. We also have $40,000 in outstanding unsecured notes that are past due. If we are unable to generate sufficient revenues and/or additional financing to service this debt, there is a risk the lenders will call the notes, secure our assets, as to those applicable secured notes, and demand payment. If this happens, we could go out of business.

 

Our investors may lose their entire investment because our financial status creates a doubt whether we will continue as a going concern.

 

We do not have sufficient cash nor do we have a significant source of revenues to cover our operational costs and allow us to continue as a going concern.  The Company anticipates generating revenues through the licensing of its core products and if that is not sufficient we may seek to raise additional operating capital to implement our business plan in an offering of our common stock or debt.  Our company's plan specifies a minimum amount of $500,000 in additional operating capital to operate for the next twelve months. However, there can be no assurance that the revenues generated or that such an offering will be successful. You may lose your entire investment

 

Our failure to raise additional capital or generate cash flows necessary to expand our operations could reduce our ability to compete successfully and adversely affect our results of operations.

 

We need to raise additional funds to achieve our future strategic objectives, and we may not be able to obtain additional debt or equity financing on favorable terms, if at all. If we engage in debt financing, we may be required to accept terms that restrict our ability to incur additional indebtedness, force us to maintain specified liquidity or other ratios or restrict our ability to pay dividends or make acquisitions. If we need additional capital and cannot raise it on acceptable terms, we may not be able to, among other things:

 

§  launch, develop and enhance our existing products;

§  continue to expand our product base, sales and/or marketing efforts;

§  hire, train and retain employees; or

§  respond to competitive pressures or unanticipated working capital requirements.

 

Our inability to do any of the foregoing could reduce our ability to compete successfully and adversely affect our results of operations.

  

If we are unable to generate revenues by implementing our business plan, you will lose your entire investment in our company.

 

We have a history of losses from inception and we had an accumulated deficit as of December 31, 2022 of $36,998,048. We have not been able to generate sufficient revenues from licensees, from the sale of our own products or otherwise to cover our expenses. If we are unsuccessful in generating revenues, you could lose your entire investment.

 

 7 

 

If our products or products that are licensed by our licensees are not deemed desirable and suitable for purchase and we cannot establish a customer base, we may not be able to generate sufficient revenues, which would result in a failure of the business and a loss of any investment one makes in our company.

 

The acceptance of our products is critically important to our success. We cannot be certain that the products that we will be offering will be appealing and as a result there may not be any demand for these products and our sales could be limited and we may never realize any significant revenues. In addition, there are no assurances that if we alter or change the products we offer in the future that the demand for these new products will develop and this could adversely affect our business and any possible revenues.

 

If demand for the products that we offer or products that are licensed by our licensees slows, then our business would be materially affected.

 

Demand for our products and products of our licensees, depends on many factors, including:

 

  § the economy, and in periods of rapidly declining economic conditions, customers may defer luxury purchases or may choose alternate products;

 

  § the competitive environment in the skin care sector or sectors in which products are introduced may force us to reduce prices below our desired pricing level or increase promotional spending;

 

  § our ability to anticipate changes in consumer preferences and to meet customers’ needs for skin care products in a timely cost-effective manner;

 

  § our ability to maintain efficient, timely and cost-effective production and delivery of the products and services; and,

 

  § our ability to identify and respond successfully to emerging trends in the skin care and personal care industries.

 

For the long term, demand for product offerings may be affected by:

 

  § the ability to establish, maintain and eventually grow market share in a competitive environment;

 

  § our ability to deliver our products in the markets we intend to service, changes in government regulations, currency fluctuations, natural disasters, pandemics and other factors beyond our control may increase the cost of items we purchase, create communication issues or render product delivery difficult which could have a material adverse effect on our sales and profitability; and

 

  § restrictions on access to North American markets and supplies.

 

All of these factors could result in immediate and longer term declines in the demand for products that we offer as well as licensed products, which could adversely affect our sales, cash flows and overall financial condition.

  

Because we are new in the marketplace, we may not be able to compete effectively and increase market share.

 

Our current and potential competitors may have longer operating histories, significantly greater resources and name recognition, and a larger base of customers than we have. Our competitors may also be able to adopt more aggressive pricing policies and devote greater resources to the development, marketing and sale of their products and services than we can. To be competitive, we must continue to invest significant resources in sales and marketing. We may not have sufficient resources to make these investments or to develop the technological advances necessary to be competitive, which in turn will cause our business to suffer and restrict our profitability potential.

 

 8 

 

Because we rely on third parties to manufacture our products, we are subject to factors outside of our control to meet our standards or timelines.

 

Our products are manufactured by three third-party manufacturing companies on a purchase order basis. No contractual arrangement are currently in place, except for standard confidentiality agreements. We are dependent on the timeliness and effectiveness of our third-part manufacturers’ efforts.

 

Failure or lack of reliability in the manufacture of our products is likely to result in loss of business. Among other risks:

 

  § Our products may fail to provide the expected results;

 

  § We may experience limited availability of quality ingredients for manufacturing;

 

  § We may experience poor quality manufacturing;

 

  § Our products may have new competition from other companies attempting to duplicate our formulas; and

 

  § Our customers could experience results different from our test results.

 

Like other retailers, distributors and manufacturers of skin care and personal care products, we face an inherent risk of exposure to product liability claims in the event that the use of the products that we sell results in injury.

 

We may be subjected to various product liability claims, including claims that the products we sell contain contaminants, are improperly labeled or include inadequate instructions as to use or inadequate warnings concerning side effects and interactions with other substances. In addition, we may be forced to defend lawsuits. We cannot predict whether product liability claims will be brought against us in the future or the effect of any resulting adverse publicity on the business. Moreover, we may not have adequate resources in the event of a successful claim against us. The successful assertion of product liability claim against us could result in potentially significant monetary damages. In addition, interactions of the products with other similar products, prescription medicines and over-the-counter drugs have not been fully explored.

 

We may also be exposed to claims relating to product advertising or product quality. People may purchase our products expecting certain physical results, unique to skin care and personal care products. If they do not perceive expected results to occur, certain individuals or groups of individuals may seek monetary retribution.

 

 If our products become contaminated, our business could be seriously harmed.

 

We have adopted various quality, environmental, health and safety standards. However, our products may still not meet these standards or could otherwise become contaminated. A failure to meet these standards or contamination could occur in our operations or those of our bottlers, manufacturers, distributors or suppliers. Such a failure or contamination could result in expensive production interruptions, recalls and liability claims. Moreover, negative publicity could be generated even from false, unfounded or nominal liability claims or limited recalls. Any of these failures or occurrences could negatively affect our business and financial performance.

 

Our business may be adversely affected by unfavorable publicity within the skin care markets.

 

Management believes that the skin care market and personal care markets are significantly affected by national media attention. As with any retail provider, future scientific research or publicity may not be favorable to the industry or to any particular product, and may not be consistent with earlier favorable research or publicity. Because of our dependence on consumers’ perceptions, adverse publicity associated with illness or other adverse effects resulting from the use of our products or any similar products distributed by other companies and future reports of research that are perceived as less favorable or that question earlier research, could have a material adverse effect on our business, financial condition and results of operations. We are highly dependent upon consumers’ perceptions of the safety and quality of the products as well as similar products distributed by other companies. Thus, the mere publication of reports asserting that skin care or personal care products may be harmful or questioning their efficacy could have a material adverse effect on our business, financial condition and results of operations, regardless of whether such reports are scientifically supported or whether the claimed harmful effects would be present at the dosages recommended for such products.

 

 9 

 

As we conduct international business transactions, we will be exposed to local business risks in different countries, which could have a material adverse effect on our financial condition or results of operations.

 

We promote and sell our products internationally and our licensees do the same. International operations will be subject to risks inherent in doing business in foreign countries, including, but not necessarily limited to:

 

  § new and different legal and regulatory requirements in local jurisdictions;

 

  § potentially adverse tax consequences, including imposition or increase of taxes on transactions or withholding and other taxes on remittances and other payments by subsidiaries;

 

  § risk of nationalization of private enterprises by foreign governments;

 

  § legal restrictions on doing business in or with certain nations, certain parties and/or certain products; and,

 

  § local economic, political and social conditions, including the possibility of hyperinflationary conditions and political instability.

 

We may not be successful in developing and implementing policies and strategies to address the foregoing factors in a timely and effective manner in the locations where we will do business. Consequently, the occurrence of one or more of the foregoing factors could have a material adverse effect on our base operations and upon our financial condition and results of operations.

 

Since our products will be available over the Internet in foreign countries and we plan to have customers residing in foreign countries, foreign jurisdictions may require us to qualify to do business in their country. We will be required to comply with certain laws and regulations of each country in which we conduct business, including laws and regulations currently in place or which may be enacted related to Internet services available to the residents of each country from online sites located elsewhere.

 

Because of the nature of our products, we may be subject to government regulations or laws that increase our costs of operations or decrease our ability to generate income.

 

Any failure by us, or by any third party that may manufacture or market our products, to comply with the law, including statutes and regulations administered by the FDA or other U.S. or foreign regulatory authorities, could result in, among other things, warning letters, fines and other civil penalties, suspension of regulatory approvals and the resulting requirement that we suspend sales of our products, refusal to approve pending applications or supplements to approved applications, export or import restrictions, interruption of production, operating restrictions, closure of the facilities used by us or third parties to manufacture our product candidates, injunctions or criminal prosecution. Any of the foregoing actions could have a material adverse effect on our business.

 

Our commercial success depends significantly on our ability to develop and commercialize our potential products without infringing the intellectual property rights of third parties.

 

Our commercial success will depend, in part, on operating our business without infringing the patents or proprietary rights of third parties. Third parties that believe we are infringing on their rights could bring actions against us claiming damages and seeking to enjoin the development, marketing and distribution of our products. If we become involved in any litigation, it could consume a substantial portion of our resources, regardless of the outcome of the litigation. If any of these actions are successful, we could be required to pay damages and/or to obtain a license to continue to develop or market our products, in which case we may be required to pay substantial royalties. However, any such license may not be available on terms acceptable to us or at all. Ultimately, we could be prevented from commercializing a product or forced to cease some aspect of our business operations as a result of patent infringement claims, which would harm our business.

 

 10 

 

The implementation of our business plan relies on our ability to manage growth. If we are not able to manage the growth, our business plan may not be successfully implemented.

 

We expect to expand our operations by increasing our sales and marketing efforts, research and development activities, and escalating our services. The anticipated growth could place a significant strain on our management, and operational and financial resources. Effective management of the anticipated growth shall require expanding our management and financial controls, hiring additional appropriate personnel as required, and developing additional expertise by existing management personnel. However, there can be no assurances that these or other measures we may implement shall effectively increase our capabilities to manage such anticipated growth or to do so in a timely and cost-effective manner. Moreover, management of growth is especially challenging for a company with a short revenue generating history and limited financial resources, and the failure to effectively manage growth could have a material adverse effect on our operations.

 

Our success depends on continuing to hire and retain qualified personnel, including our director and officers and our technical personnel.  If we are not successful in attracting and retaining these personnel, our business will suffer.

 

Our success depends substantially on the performance of our management team and key personnel. Currently, we have three employees, including our CEO Terry Howlett. Due to the specialized technical nature of our business, we are particularly dependent on our technical personnel. Our future success will depend on our ability to attract, integrate, motivate and retain qualified technical, sales, operations, and managerial personnel, as well as our ability to successfully implement a plan for management succession. Competition for qualified personnel in our business areas is intense, and we may not be able to continue to attract and retain key personnel. In addition, if we lose the services of any of our management team or key personnel and are not able to find suitable replacements in a timely manner, our business could be disrupted and we may incur increased operating expenses.

 

 If we are unable to attract new distributors and customers, or if our existing distributors and customers do not purchase additional products, the growth of our business and cash flows will be adversely affected.

 

To increase our revenues and cash flows, we must regularly add distributors and customers and sell additional products to our existing distributors and customers. If we are unable to sell our products to customers that have been referred to us, unable to generate sufficient sales leads through our marketing programs, or if our existing or new distributors and customers do not perceive our products to be of sufficiently high value and quality, we may not be able to increase sales and our operating results would be adversely affected. In addition, if we fail to sell new products to existing distributors and customers or new distributors and customers, our operating results will suffer, and our revenue growth, cash flows and profitability may be materially and adversely affected.

 

 Key management personnel may leave us, which could adversely affect our ability to continue operations.

 

We are entirely dependent on the efforts of our management because of the time and effort that they devote to us. They are in charge of overseeing all development strategies, supervising any/all future personnel, and the implementation of our business plan. Their loss, or other key personnel in the future, could have a material adverse effect on our business, financial condition and results of operations.

 

Risks Related to Our Securities

 

If a market for our common stock does not develop, shareholders may be unable to sell their shares.

 

Our common stock is quoted under the symbol “SKVI” on the OTCQB operated by OTC Markets Group, Inc, an electronic inter-dealer quotation medium for equity securities. We do not currently have an active trading market. There can be no assurance that an active and liquid trading market will develop or, if developed, that it will be sustained.

 

Our securities are very thinly traded. Accordingly, it may be difficult to sell shares of our common stock without significantly depressing the value of the stock. Unless we are successful in developing continued investor interest in our stock, sales of our stock could continue to result in major fluctuations in the price of the stock.

 

 11 

 

Our common stock price may be volatile and could fluctuate widely in price, which could result in substantial losses for investors.

 

The market price of our common stock is likely to be highly volatile and could fluctuate widely in price in response to various factors, many of which are beyond our control, including:

 

  • technological innovations or new products and services by us or our competitors;
  • government regulation of our products and services;
  • the establishment of partnerships with other technology companies;
  • intellectual property disputes;
  • additions or departures of key personnel;
  • sales of our common stock
  • our ability to integrate operations, technology, products and services;
  • our ability to execute our business plan;
  • operating results below expectations;
  • loss of any strategic relationship;
  • industry developments;
  • economic and other external factors; and
  • period to period fluctuations in our financial results.

Because we have nominal revenues to date, you should consider any one of these factors to be material. Our stock price may fluctuate widely as a result of any of the above.

 

In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.

 

We have not paid cash dividends in the past and do not expect to pay cash dividends in the future on our common stock. Any return on investment may be limited to the value of our common stock.

 

We have never paid cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future. The payment of cash dividends on our common stock will depend on earnings, financial condition and other business and economic factors at such time as the board of directors may consider relevant. If we do not pay cash dividends, our common stock may be less valuable because a return on your investment will only occur if its stock price appreciates.

 

 As a new investor, you will experience substantial dilution as a result of future equity issuances.

 

In the event we are required to raise additional capital it may do so by selling additional shares of common stock thereby diluting the shares and ownership interests of existing shareholders.

 

Because we are subject to the “Penny Stock” rules, the level of trading activity in our stock may be reduced.

 

The Securities and Exchange Commission has adopted regulations which generally define "penny stock" to be any listed, trading equity security that has a market price less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exemptions. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer must also provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer’s account. In addition, the penny stock rules generally require that prior to a transaction in a penny stock, the broker-dealer make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for a stock that becomes subject to the penny stock rules which may increase the difficulty Purchasers may experience in attempting to liquidate such securities.

 

 12 

 

Provisions in the Nevada Revised Statutes and our Bylaws could make it very difficult for an investor to bring any legal actions against our directors or officers for violations of their fiduciary duties or could require us to pay any amounts incurred by our directors or officers in any such actions.

 

Members of our board of directors and our officers will have no liability for breaches of their fiduciary duty of care as a director or officer, except in limited circumstances, pursuant to provisions in the Nevada Revised Statutes and our Bylaws as authorized by the Nevada Revised Statutes. Specifically, Section 78.138 of the Nevada Revised Statutes provides that a director or officer is not individually liable to the company or its shareholders or creditors for any damages as a result of any act or failure to act in his or her capacity as a director or officer unless it is proven that (1) the director’s or officer’s act or failure to act constituted a breach of his or her fiduciary duties as a director or officer and (2) his or her breach of those duties involved intentional misconduct, fraud or a knowing violation of law. This provision is intended to afford directors and officers protection against and to limit their potential liability for monetary damages resulting from suits alleging a breach of the duty of care by a director or officer. Accordingly, you may be unable to prevail in a legal action against our directors or officers even if they have breached their fiduciary duty of care. In addition, our Bylaws allow us to indemnify our directors and officers from and against any and all costs, charges and expenses resulting from their acting in such capacities with us. This means that if you were able to enforce an action against our directors or officers, in all likelihood, we would be required to pay any expenses they incurred in defending the lawsuit and any judgment or settlement they otherwise would be required to pay. Accordingly, our indemnification obligations could divert needed financial resources and may adversely affect our business, financial condition, results of operations and cash flows, and adversely affect prevailing market prices for our common stock.

  

Item 2. Properties

 

Currently, we do not own any or lease any real estate.

  

Item 3. Legal Proceedings

 

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

 

Item 4. Mine Safety Disclosures

 

Not Applicable

 

 13 

 

PART II

 

Item 5. Market for Registrant’s Common Equity and Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Market Information

 

Our common stock is quoted under the symbol “SKVI” on the OTCQB operated by OTC Markets Group, Inc. 

 

The OTCQB is a quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter equity securities. Because our stock is traded on the OTCQB, these quotations reflect inter-dealer prices, without retail markup, markdown or commission and may not represent actual transactions. Because we are quoted on the OTCQB, our securities may be less liquid, receive less coverage by security analysts and news media, and generate lower prices than might otherwise be obtained if they were listed on a national securities exchange.

 

Trading in stocks quoted on the OTCQB is often thin and is characterized by wide fluctuations in trading prices due to many factors that may be unrelated to a company’s operations or business prospects. We cannot assure you that there will be a market in the future for our common stock.

 

The following table sets forth, for the fiscal quarters indicated, the high and low bid information for our common stock, as reported on the OTCQB. The following quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions.

 

   High  Low
Fiscal Year Ended December 31, 2021         
First Quarter  $0.11   $0.11
Second Quarter  $0.07   $0.07
Third Quarter  $0.12   $0.11
Fourth Quarter  $0.24   $0.24
          
Fiscal Year Ended December 31, 2022         
First Quarter  $0.13   $0.13
Second Quarter  $0.12   $0.12
Third Quarter  $0.17   $.017
Fourth Quarter  $0.10   $0.10

  

Penny Stock

 

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a market price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that: (a) contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading; (b) contains a description of the broker’s or dealer’s duties to the customer and of the rights and remedies available to the customer with respect to a violation of such duties or other requirements of the securities laws; (c) contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price; (d) contains a toll-free telephone number for inquiries on disciplinary actions; (e) defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and (f) contains such other information and is in such form, including language, type size and format, as the SEC shall require by rule or regulation.

 

 14 

 

The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statement showing the market value of each penny stock held in the customer’s account.

 

In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written acknowledgment of the receipt of a risk disclosure statement, a written agreement as to transactions involving penny stocks, and a signed and dated copy of a written suitability statement.

 

These disclosure requirements may have the effect of reducing the trading activity for our common stock. Therefore, stockholders may have difficulty selling our securities.

 

Holders of Our Common Stock

 

As of March 31, 2023, we had 4,539,843 shares of our common stock issued and outstanding, held by ___ shareholders of record, other than those held in street name.

 

Dividends

 

There are no restrictions in our articles of incorporation or bylaws that prevent us from declaring dividends. The Nevada Revised Statutes, however, do prohibit us from declaring dividends where after giving effect to the distribution of the dividend:

 

1. we would not be able to pay our debts as they become due in the usual course of business, or;
2. our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of shareholders who have preferential rights superior to those receiving the distribution.

 

We have not declared any dividends and we do not plan to declare any dividends in the foreseeable future.

 

Recent Sales of Unregistered Securities

 

 During the years ended December 31, 2021 and 2022 and to the date of filing this Annual Report, we have not issued any shares of common stock_.

 

These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

The following table provides information about our compensation plans under which shares of common stock may be issued upon the exercise of options as of December 31, 2022.

 

In July 2006, we adopted the 2006 Skinvisible, Inc. Stock Option Plan, which provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, performance shares and performance units, and stock awards our officers, directors or employees of, as well as advisers and consultants. This plan was confirmed by our stockholders on August 7, 2006 at the annual shareholders meeting.

 

Under the 2006 Skinvisible, Inc. Stock Option Plan, we reserved 200,000 shares of common stock for the granting of options and rights.

 

 15 

 

Equity Compensation Plans as of December 31, 2022

    A   B   C
Plan Category     Number of securities to be issued upon exercise of outstanding options, warrants and rights       Weighted-average exercise price of outstanding options,
warrants and right
      Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (A))
Equity compensation plans approved by security holders     100,000     $ 1.51       39,000
Equity compensation plans not approved by security holders     60,000     $ 1.11       —  
Total     160,000     $ 1.31       39,000 

 

Item 6. Selected Financial Data

 

A smaller reporting company is not required to provide the information required by this Item.

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

  

Forward-Looking Statements

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

 

COVID-19

 

The full extent of the impact of the COVID-19 pandemic on our business, operations and financial results will depend on numerous evolving factors that we may not be able to accurately predict at the present time. In an effort to contain COVID-19 or slow its spread, governments around the world have enacted various measures, including orders to close all businesses not deemed “essential,” isolate residents to their homes or places of residence, and practice social distancing when engaging in essential activities. We anticipate that these actions and the global health crisis caused by COVID-19 will negatively impact business activity across the globe. While we have not observed any noticeable impact on our revenue related to these conditions in the past fiscal year, or through the date of this filing, we cannot estimate the impact COVID-19 will have in the future as business and consumer activity decelerates across the globe.

 

We will continue to actively monitor the situation and may take further actions that alter our business operations as may be required by federal, state, local or foreign authorities, or that we determine are in the best interests of our employees, customers, partners and stockholders. It is not clear what the potential effects any such alterations or modifications may have on our business, including the effects on our customers, partners, or vendors, or on our financial results.

 

 16 

 

Results of Operations for the Years Ended December 31, 2022 and 2021

 

Revenues

 

Our revenue, which we combine from product sales, royalties on patent licenses and license fees (product development fees), was $279,296for the year ended December 31, 2022, an decrease from $663,426 for the same period ended December 31, 2021.

 

The revenue for 2022 was mainly from license fees with Quoin and the revenue for 2021 was mainly from license fees with Quoin and Ovation. We hope to generate more revenues from our licenses with Quoin and Ovation in2023.

 

Gross Profit

 

We had $4,808 in cost of revenues for the year ended December 31, 2022, as compared with $3,300 in cost of revenues for the year ended December 31, 2021, so our gross profit was $274,488, or 98% of sales for 2022 and $660,126, or 99% of sales for 2021.

 

Our gross profit decreased in 2022 due to less revenues from our license with Quoin, We hope to generate more revenues from our licenses with Quoin and Ovation in2023.

 

Operating Expenses

 

Operating expenses decreased to $512,919 for the year ended December 31, 2022 from $472,046 for the same period ended December 31, 2021.

 

Our operating expenses for all periods consisted mainly of selling, general and administrative expenses.

 

Our selling, general and administrative expenses for the year December 31, 2022 consisted mainly of accrued salaries and wages of $328,769 and audit and accounting of $53,638. In comparison, our selling, general and administrative expenses for the year ended December 31, 2021 consisted mainly of accrued salaries and wages of $316,769, audit and accounting of $49,712.

 

Other Expenses

 

We had other expenses of $986,455 for the year ended December 31, 2022, as compared with other expenses of $1,260,833 for the year ended December 31, 2021.

 

Our other expenses for the year ended December 31, 2022 consisted mainly of interest expense, netted against a gain on forgiveness of debt and gain on derivative liability changes. Our other expenses for the year ended December 31, 2021 consisted mainly of interest expense and a loss on the changes in derivative liability, offset by a gain on the settlement of debt.

 

Net Loss

 

We recorded a net loss of $1,224,887 for the year ended December 31, 2022, as compared with a net loss of $1,072,753 for the year ended December 31, 2021.

 

Liquidity and Capital Resources

 

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $36,998,048 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to generate the necessary funds through licensing of its core products or the ability to raise additional capital through the future issuances of common stock or debt is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. These factors, among others, raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

 17 

 

As of December 31, 2022, we had total current assets of $109,946 and total assets in the amount of $246,793. Our total current liabilities as of December 31, 2022 were $3,644,986. We had a working capital deficit of $3,535,040 as of December 31, 2022, compared with a working capital deficit of $2,987,049 as of December 31, 2022.

 

Operating activities provided $45,170 in cash for the year ended December 31, 2022, as compared with $374,605 provided for the year ended December 31, 2021. Our positive operating cash flows for 2022 and 2021 was largely the result of changes in operating assets and liabilities, amortization of debt discount offset mainly by the net loss for the periods.

 

We used cash of $2.530 and $20,864 in investing activities for the years ended December 31, 2022 and 2021, respectively, for the purchase of fixed and intangible assets.

 

Cash flows used by financing activities during the year ended December 31, 2022 amounted to $27,299, as compared with cash used of $323,600 for the year ended December 31, 2021. Our negative financing cash flow for the year ended December 31, 2022 resulted from payments on related party loans. Our negative financing cash flow for the year ended December 31, 2021 resulted from the repayments of debt.

 

The features of the debt instruments and payables concerning our financing activities are detailed in the footnotes to our financial statements.

 

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising addition

 

Off Balance Sheet Arrangements

 

As of December 31, 2022, there were no off-balance sheet arrangements.

 

Critical Accounting Policies

 

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

 

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

 

Royalty sales – We also recognize royalty revenue from licensing our patented product formulations only when earned, with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

 

Distribution and license rights sales – We also recognize revenue from distribution and license rights only when earned (and are amortized over a five-year period), with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

 

Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

 

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of December 31, 2022, we had not recorded a reserve for doubtful accounts.

 

 18 

 

Recently Issued Accounting Pronouncements

 

In August 2020, FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity; Own Equity (“ASU 2020-06”), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity, and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company’s current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company is currently evaluating the impact the adoption of ASU 2020-06 will have on the Company’s financial statements.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 

A smaller reporting company is not required to provide the information required by this Item.

 

Item 8. Financial Statements and Supplementary Data

 

Index to Financial Statements Required by Article 8 of Regulation S-X:

 

Audited Financial Statements:

 

F-1 Report of Independent Registered Public Accounting Firm (ID:)
F-2 Consolidated Balance Sheets as of December 31, 2022 and 2021
F-3 Consolidated Statements of Operations for the years ended December 31, 2022 and 2021
F-4 Consolidated Statement of Stockholders’ Deficit for the years ended December 31, 2022 and 2021
F-5 Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021
F-6 Notes to Consolidated Financial Statements

  

 19 

 

 

   

Gries & Associates, LLC

Certified Public Accountants

501 S. Cherry Street Ste 1100

Denver, Colorado 80246

 
       

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders
Skinvisible, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Skinvisible, Inc. (the Company), which comprise the balance sheet as of December 31, 2022 and 2021 and the related statements of Operations, Changes in Stockholder’s Equity, and Cash Flows for the years then ended, and the related notes to the financial statements. In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the period then ended in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United Sates) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we were required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluation of the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgements. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the disclosures to which it relates.

 

 

Emphasis of Matter Regarding Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 2 to the financial statements, the Company has not generated any revenues since inception and sustained a net loss of $1,224,887 for the year under audit and has accumulated losses of $36,998,048. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter.

 

Emphasis of Matters-Risks and Uncertainties

 

The Company is not able to predict the ultimate impact that COVID -19 will have on its business. However, if the current economic conditions continue, the pandemic could have an adverse impact on the economies and
financial markets of many countries, including the geographical area in which the Company plans to operate.

 

/s/ Gries & Associates, LLC

   
   
  We have served as the Company’s auditor since 2021.
     
 

Denver, Colorado

March 28, 2023 

PCAOB #6778

 

 

 

     
 

blaze@griesandassociates.com

 
  501 S. Cherry Street Suite 1100, Denver, Colorado 80246  
  (O)720-464-2875 (M)773-255-5631 (F)720-222-5846  

 

 F-1 

 

SKINVISIBLE, INC.

CONSOLIDATED BALANCE SHEETS

(AUDITED)

 

   December 31, 2022  December 31, 2021
ASSETS      
Current assets          
Cash  $81,378   $66,037 
Accounts receivable   19,073    82 
Prepaid expense and other current assets   9,495    8,125 
Total current assets   109,946    74,244 
           
Patents and trademarks, net   136,847    153,055 
           
Total assets  $246,793   $227,299 
          .  
LIABILITIES AND STOCKHOLDERS' DEFICIT          
Current liabilities          
Accounts payable and accrued liabilities  $1,201,937   $1,039,661 
Accrued interest payable   1,955,820    1,475,067 
Loans from related party         27,299 
Loans payable   433,600    433,600 
Convertible notes payable   40,000    40,000 
Derivative liability   13,629    45,664 
Total current liabilities   3,644,986    3,061,293 
           
Convertible notes payable related party, net of unamortized discount of $1,228,066 and $1,837,918 respectively   2,992,143    2,382,291 
Convertible notes payable, net of unamortized debt discount of $101,808 and $152,642, respectively   250,267    199,433 
           
Total liabilities   6,887,396    5,643,017 
           
Stockholders' deficit          
Common stock; $0.001 par value; 200,000,000 shares authorized; 4,539,843 shares issued and outstanding at December 31, 2022 and 2021, respectively   4,540    4,540 
Additional paid-in capital   30,352,905    30,352,905 
Accumulated deficit   (36,998,048)   (35,773,161)
Total stockholders' deficit   (6,640,603)   (5,415,716)
           
Total liabilities and stockholders' deficit  $246,793   $227,299 

 

See Accompanying Notes to Consolidated Financial Statements.

 F-2 

 

SKINVISIBLE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(AUDITED)

                 
   Years ended
   December 31, 2022  December 31, 2021
       
       
Revenues  $279,296   $663,426 
           
Cost of revenues   4,808    3,300 
           
Gross profit   274,488    660,126 
           
Operating expenses          
Depreciation and amortization   18,738    17,939 
Selling general and administrative   494,182    454,107 
Total operating expenses   512,920    472,046 
           
Loss from operations   (238,432)   188,080 
           
Other income and (expense)          
Interest expense   (1,162,869)   (1,213,043)
Loss on change in derivative liability   32,035    (157,478)
Gain/(loss) on settlement of debt   144,379    109,688 
Total other income (expense)   (986,455)   (1,260,833)
           
Net income (loss)  $(1,224,887)  $(1,072,753)
           
Basic income (loss) per common share  $(0.27)  $(0.24)
           
Fully diluted income (loss) per common share  $(0.27)  $(0.24)
           
Basic weighted average common shares outstanding   4,539,843    4,539,843 
           
Fully diluted weighted average common shares outstanding   4,539,843    4,539,843 

 

See Accompanying Notes to Consolidated Financial Statements.

 

 F-3 

 

SKINVISIBLE, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT

(AUDITED)

                                                 
   Common Stock            
   Shares  Amount  Additional Paid-in Capital  Shares payable  Accumulated Deficit  Total Stockholders'  Deficit
 Balance, December 31, 2020   4,539,843   $4,540   $30,241,089   $     $(34,700,408)  $(4,454,779)
 Derivative liability written off to APIC               111,816                111,816 
 Net loss                           (1,072,753)   (1,072,753)
 Balance, December 31, 2021   4,539,843    4,540    30,352,905          (35,773,161)   (5,415,716)
 Net loss                           (1,224,887)   (1,224,887)
 Balance, December 31, 2022   4,539,843    4,540    30,352,905          (36,998,048)   (6,640,603)

 

 

 

See Accompanying Notes to Consolidated Financial Statements.

 

 F-4 

 

SKINVISIBLE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(AUDITED) 

                 
   Years ended
   December 31, 2022  December 31, 2021
       
Cash flows from operating activities:          
Net Income (loss)  $(1,224,887)  $(1,072,753)
Adjustments to reconcile net loss to net cash provided (used) by operating activities:          
Depreciation and amortization   18,738    17,939 
Amortization of debt discount   660,686    645,686 
Gain/(loss) on settlement of debt   (144,379)   (109,688)
Loss on change in derivative liability   (32,035)   157,478 
Changes in operating assets and liabilities:          
Decrease (Increase) in prepaid assets   (1,370)   (1,625)
Decrease (Increase) in accounts receivable   (18,991)   7,636 
Increase in accounts payable and accrued liabilities   306,655    174,166 
Decrease in due from related party         (7,616)
Increase in accrued interest   480,753    563,382 
Net cash provided by (used in) operating activities   45,170    374,605 
           
Cash flows from investing activities:          
Purchase of fixed and intangible assets   (2,530)   (20,864)
Net cash used in investing activities   (2,530)   (20,864)
           
Cash flows from financing activities:          
Payments on related party loans   (27,299)   (25,200)
Payments on loans payable         (180,000)
Payments on convertible notes payable         (118,400)
           
Net cash used in financing activities   (27,299)   (323,600)
           
Net change in cash   15,341    30,141 
           
Cash, beginning of period   66,037    35,896 
           
Cash, end of period  $81,378   $66,037 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $     $12,631 
Cash paid for tax  $     $   
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Non-cash investing and financing activities:          
Beneficial conversion feature on convertible debt  $     $   
Common stock issued on extinguishment of debts  $     $   
Common stock payable on extinguishment of debts  $     $59,602 

 

See Accompanying Notes to Consolidated Financial Statements.

 

 F-5 

 

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

  

1.       DESCRIPTION OF BUSINESS AND HISTORY

 

Description of business

Skinvisible, Inc., (referred to as the “Company”) is focused on the development, manufacture and sales of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations offer solutions for a broad spectrum of markets including women’s health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.

 

History

The Company was incorporated in Nevada on March 6, 1998, under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.

 

Skinvisible, Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.”

 

2.       BASIS OF PRESENTATION AND GOING CONCERN

 

Basis of presentation

The accompanying audited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the period presented have been reflected herein.

 

Going concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. For the year ended December 31, 2022, the Company had a net loss of $1,224,887 The Company has also incurred cumulative net losses of $36,998,048 since its inception and requires capital for its contemplated operational and marketing activities to take place. These factors, among others, raises substantial doubt about the Company’s ability to continue as a going concern within one year from the date of filing. Managements plans for the Company are to generate the necessary funding through licensing of its core products and to seek additional debt and equity funding. However, the Company’s ability to generate the necessary funds through licensing or raise additional capital through the future issuances of common stock or debt is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

The Company's operations and business have experienced disruption due to the unprecedented conditions surrounding the COVID-19 pandemic spreading throughout the United States and elsewhere. The spread of COVID-19 has caused a change in the availability of our staff and support services. Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this filing. These estimates could change in the future, as new events occur, or additional information is obtained. 

  

3.       SUMMARY OF SIGNIFICANT POLICIES

 

This summary of significant accounting policies of Skinvisible Inc. is presented to assist in understanding the Company’s consolidated financial statements. The consolidated financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the consolidated financial statements.  

 

Principles of consolidation

The consolidated financial statements include the accounts of the Company and its subsidiary Skinvisible Pharmaceuticals Inc. All significant intercompany balances and transactions have been eliminated.

 

 F-6 

 

Use of estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s impairments and estimations of long-lived assets, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

Cash and cash equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be cash equivalents.

 

Fair Value of financial instruments

The carrying value of cash, accounts payable and accrued expenses, and debt (See Notes 6 & 8) approximate their fair values because of the short-term nature of these instruments. Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments. The carrying amount of the Company’s convertible debt is also stated at a fair value of $4,572,284 since the stated rate of interest approximates market rates.

 

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable.

 

  Level 1 Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets. The Company uses Level 1 measurements to value the transactions when it issues shares, warrants, options and debt with beneficial conversion features.

 

  Level 2 Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily available pricing sources for comparable instruments. The Company did not rely on any Level 2 measurements for any of its transactions in the periods included in these financial statements.

 

  Level 3 Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances. The Company did not rely on any Level 3 measurements for any of its transactions in the periods included in these financial statements.

 

Revenue recognition

We recognize revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board's (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which requires that five steps be followed in evaluating revenue recognition: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.

 

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

 

Royalty sales – We also recognize royalty revenue from licensing our patented product formulations only when earned, with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

 

Distribution and license rights sales – We also recognize revenue from distribution and license rights when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

 

 F-7 

 

The Company has made an accounting policy election to exclude from the measurement of the transaction price all taxes assessed by governmental authorities that are collected by the Company from its customers (sales and use taxes, value added taxes, some excise taxes).

 

Accounts Receivable

Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of December 31, 2022 and 2021, the Company had determined it was not necessary to recognize a reserve for doubtful accounts.

 

Intangible assets

The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other”. According to this statement, intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test.  Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

 

Income taxes

The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

Stock-based compensation

The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to an Employee Stock Purchase Plan based on the estimated fair values.

 

Earnings (loss) per share

The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented for the year ending December 31, 2022 since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect. There are 23,609,820 additional shares issuable in connection with outstanding options, warrants, stock payable and convertible debts as of December 31, 2022 The shares issuable under each instrument is as follows; 23,609,820 shares issuable under convertible notes.

  

Recently issued accounting pronouncements

The Company has evaluated all other recent accounting pronouncements and believes that none of them will have a material effect on the Company's financial position, results of operations or cash flows.

 

 F-8 

 

4.        RELATED PARTY TRANSACTIONS

 

During the year ended December 31, 2022 and 2021, $27,299 and $25,200 in advances were repaid to an officer of the Company.

 

As of December 31, 2022 and 2021, $0 and $27,299 in advances, respectively, remained due to officers of the Company.

  

Convertible Notes Related Party 

               
Convertible Notes Payable Related Party consists of the following:   December 31, 2022   December 31, 2021
On June 30, 2019, the Company renegotiated accrued salaries, accrued interest, unpaid reimbursements, cash advances, and outstanding convertible notes for its two officers. Under the terms of the agreements, all outstanding notes totaling $2,464,480, accrued interest of $966,203, accrued salaries of $617,915, accrued vacation of $64,423, unpaid reimbursements of $11,942 and cash advances of $110,245 were converted to promissory notes convertible into common stock with a warrant feature. The convertible promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date.
 
The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $3,369,244. The aggregate beneficial conversion feature associated with these notes has been accreted and charged to interest expenses as a financing expense in the amount of $609,852 during the year ended December 31, 2022 and $609,200 for the year ended December 31, 2021. The Company made payments toward the principal balance of the notes of $0 and $15,000 for the years ended December 31, 2022 and 2021, respectively.
  $ 4,220,209     $ 4,220,209
Unamortized debt discount     (1,228,066 )     (1,837,918)
Total, net of unamortized discount   $ 2,992,143     $ 2,382,291

 

5.       INTANGIBLE AND OTHER ASSETS

 

Patents and other intangible assets are capitalized at their historical cost and are amortized over their estimated useful lives. As of December 31, 2022 intangible assets total $136,847, net of $148,273 of accumulated amortization. As of December 31, 2021, intangible assets total $153,591, net of $129,535 of accumulated amortization.

 

License and distributor rights were acquired by the Company in January 1999 and provide exclusive use distribution of polymers and polymer based products. The Company has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license and distribution rights for impairment and has determined that no impairment write-down is considered necessary as of December 31, 2022.

 

6.       NOTES PAYABLE

 

Secured debt offering

 

During the period from May 22, 2013 and December 31, 2018, the Company entered into a 9% notes payable to nineteen investors and received proceeds of $552,000. The notes were due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods.”

 

As of December 31, 2022, $433,600 of the outstanding notes payable are past due and in default and have been classified as current notes payable.

 

 F-9 

 

7.       CONVERTIBLE NOTES PAYABLE

               
Convertible Notes Payable consists of the following:   December 31,   December 31,
    2022   2021
$40,000 face value 9% secured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The notes have reached maturity and are now in default, under the notes default provisions the entire balance is now due upon demand.     40,000       40,000
Original issue discount                
Unamortized debt discount                
Total, net of unamortized discount     40,000       40,000
               
On June 30, 2019, the Company renegotiated accrued salaries and interest and outstanding convertible notes for a former employee. Under the terms of the agreements, all outstanding notes totaling $224,064, accrued interest of $119,278, accrued salaries of $7,260 and accrued vacation of $1,473 were converted to a promissory note convertible into common stock with a warrant feature. The convertible promissory note is unsecured, due five years from issuance, and bears an interest rate of 10%. At the noteholder’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date.
 
The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $152,642 as valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to interest expenses in the amount of $50,974 and $51,252 for the years ended December 31, 2022 and 2021, respectively.
    352,075       352,075
Unamortized debt discount     (101,808 )     (152,642
Total, net of unamortized discount     250,267       199,433

 

 Total Convertible Notes   $ 290,267     $ 239,433
Current portion:     40,000       40,000
Total long-term convertible notes   $ 250,267     $ 199,433

 

8.    COMMITMENTS AND CONTINGENCIES

 

License Agreement

 

On October 17, 2019, Skinvisible entered an Exclusive License Agreement with Quoin pursuant to which Skinvisible granted to Quoin a license to certain patents for the development of products for commercial sale. In exchange for the license, Quoin agreed to pay to Skinvisible a license fee of $1,000,000 and a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations. The agreement also requires that Quoin make certain milestone payments to Skinvisible upon achieving regulatory approval milestones for certain drug products.

 

 F-10 

 

The agreement is subject to termination, if among other things, 50% of the license fee is not paid by December 31, 2019 and if the full License Fee is not paid by March 31, 2020. No payments were made by Quoin and the agreement was terminated on December 31, 2019. Both Parties subsequently determined that they continue to see the value in a partnership and therefore on May 8, 2020 and again on July 31, 2020 the companies agreed to extend the Exclusive License Agreement, as amended under the same terms to expire on September 30, 2020   and on January 27, 2021 the companies agreed to revise the milestone payments due under the agreement and to extend the agreement indefinitely.

 

On June 14, 2021, the Company entered into an amendment to change the terms of the license Fee as shown below.

 

As partial consideration for the rights conveyed by Skinvisible under this Agreement, Licensee agrees to pay to Skinvisible a one-time, non-refundable, non-creditable license issue fee of one million USD dollars (USO $1,000,000) (''License Fee'').

 

As of December 31, 2022, the Company has recognized $1,000,000 under the agreement including $250,000 during the year ended December 31, 2022.

 

On February 3, 2020, we entered into a License Agreement with Ovation Science Inc. pursuant to which Skinvisible granted to Ovation Science Inc. a license for the manufacture and distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay to Skinvisible a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations plus a license fee payable in year 3 of the agreement if it chooses to continue the license. On June 10, 2020, the agreement was further amended to provide additional assignment rights for its hand sanitizer products in exchange for $100,000

 

9.    INCOME TAXES  

 

The Company provides for income taxes under FASB ASC 740, Accounting for Income Taxes. FASB ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect currently.

FASB ASC 740 requires the reduction of deferred tax assets by a valuation allowance, if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. In the Company’s opinion, it is uncertain whether they will generate sufficient taxable income in the future to fully utilize the net deferred tax asset. Accordingly, a valuation allowance equal to the deferred tax asset has been recorded. The total deferred tax asset is approximately $7.8 million as of December 31, 2022 which is calculated by multiplying a 21% estimated tax rate by the cumulative net operating loss (NOL) of approximately $37.0 million.

Due to the enactment of the Tax Reform Act of 2017, we have calculated our deferred tax assets using an estimated corporate tax rate of 21%. US Tax codes and laws may be subject to further reform or adjustment which may have a material impact to the Company’s deferred tax assets and liabilities.

The Company will recognize interest and penalties related to uncertain tax positions as a component of income tax expense. As of December 31, 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company’s statement of operations.

The significant components of the Company's deferred tax assets and liabilities as of December 31, 2022 and 2021 are as follows:

As of December 31,  2022  2021
Cumulative tax net operating losses (in millions)  $37.0   $15.7 
           
Deferred tax asset (in millions)  $7.8   $3.3 
Valuation allowance (in millions)   (7.8)   (3.3 
Current taxes payable            
Income tax expense  $     $   

 

As of December 31, 2022 and 2021, the Company had gross federal net operating loss carryforwards of approximately $37.0 million and $15.7 million, respectively. The Company’s net operating loss carryforwards begin expiring in 2028. The current year’s net operating loss will carryforward indefinitely, limited to 80% of the current year taxable income.

The Company plans to file its U.S. federal return for the year ended December 31, 2022 upon the issuance of this filing. Upon filing of the tax return for the year ended December 31, 2022 the actual deferred tax asset and associated valuation allowance available to the Company may differ from management’s estimates. The tax years 2018-2020 remained open to examination for federal income tax purposes by the major tax jurisdictions to which the Company is subject. No tax returns are currently under examination by any tax authorities.

 F-11 

 

10.       STOCK OPTIONS AND WARRANTS

 

Stock options

 

The following is a summary of option activity during the years ended December 31, 2022 and 2021.

 

   Number of Shares  Weighted Average Exercise Price
Balance, December 31, 2021   30,000    1.51 
           
Options granted and assumed            
Options expired   (30,000)      
Options canceled            
Options exercised            
           
Balance, December 31, 2022         1.51 

 

11.       STOCKHOLDERS’ DEFICIT

 

The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. The Company had 4,539,843 and 4,539,843 issued and outstanding shares of common stock as of December 31, 2022 and 2021, respectively.

  

12.       SUBSEQUENT EVENTS

 

In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to December 31, 2022 to the date these financial statements were available to be issued and has determined that it does not have any material subsequent events to disclose in these financial statements.  

 

 F-12 

 

Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

 

On January 7, 2022, Prager Metis CPAs, LLC (the “Former Accountant”) declined to stand for reappointment as our independent registered public accounting firm and, on January 12, 2022, we engaged Gries and Associates, LLC (the “New Accountant”) as our independent registered public accounting firm. The engagement of the New Accountant was approved by our Board of Directors. 

 

Item 9A. Controls and Procedures

 

As required by Rule 13a-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this annual report, being December 31, 2022. This evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under the Securities Exchange Act of 1934 is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

Based upon that evaluation, including our Chief Executive Officer and Chief Financial Officer, we have concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this annual report.

 

Management’s Annual Report on Internal Control over Financing Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934). Management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2022 based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of this assessment, management concluded that, as of December 31, 2022, our internal control over financial reporting was not effective. Our management identified the following material weaknesses in our internal control over financial reporting, which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

 

We plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this annual report on Form 10-K, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we hope to implement the following changes during our fiscal year ending December 31, 2023: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out in (i) and (ii) are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

 

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to an exemption for non-accelerated filers set forth in Section 989G of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

 

Item 9B. Other Information

 

None 

 

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 

 

None

 

 20 

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance

 

The following information sets forth the names, ages, and positions of our current directors and executive officers.

 

Name Age Position(s) and Office(s) Held
Terry Howlett 75 Chief Executive Officer, Chief Financial Officer, and Director
David St. James 50 Director

 

 

Set forth below is a brief description of the background and business experience of each of our current executive officers and directors.

 

Mr. Terry H. Howlett, has been our Chief Executive Officer and Director since March 5, 1998. Mr. Howlett has a diversified background in market initialization and development, sales and venture capital financing for emerging growth companies. He has held senior management, marketing and sales positions with various companies, including the Canadian Federation of Independent Business, Family Life Insurance, and Avacare of Canada and founded Presley Laboratories, Inc., which marketed cosmetic and skin, care products on a direct sales basis. For the ten years prior to becoming President of the Company, Mr. Howlett was the President and CEO of Voice-it Solutions, Inc., a publicly traded company on the Vancouver Stock exchange that made voice response software for order entry systems.

 

Mr. David St. James is an inventor and businessman based in Las Vegas, Nevada. He has invented and co-invented turbochargers and superchargers, some of which are in use today on production vehicles and in Formula 1. He has also been involved in other various aspects of the automotive industry, including product development, service, and repair. He has been an Officer and Director of Homeland Resources Ltd. since July of 2014 and currently serves as the President and a Director. He has been the Vice President and a Director of Nouveau Ventures Inc. since August of 2014. Mr. St. James served as the President of XLR Medical Corporation from January 2009 through January 2012. 

 

Directors

 

Our bylaws authorize no less than one (1) and more than twelve (12) directors. We currently have two directors.

 

Term of Office

 

Our Directors are appointed for a one-year term to hold office until the next annual general meeting of our shareholders or until removed from office in accordance with our bylaws. Our officers are appointed by our board of directors and hold office until removed by the board.

 

Significant Employees

 

Ms. Doreen McMorran, is head of Business Development. Ms. McMorran brings to the Company almost 20 years of experience in the medical and pharmaceutical industry, specifically in the areas of strategic planning, sales and marketing. She has spent the last seven years selling to international dermatology and skincare focused companies like Procter and Gamble, Johnson & Johnson, Stiefel, Galderma, Novartis and Graceway, to name a few. Ms. McMorran, who holds a Bachelor of Commerce (Honors) degree, spent six years in the pharmaceutical industry with Astra Pharma. Additionally, she has held senior management level positions with a number of healthcare companies, focusing on business development, sales, marketing and operations.

 

Family Relationships

 

There are no family relationships between or among the directors, executive officers or persons nominated or chosen by us to become directors or executive officers.

 

 21 

 

Involvement in Certain Legal Proceedings

 

To the best of our knowledge, during the past ten years, none of the following occurred with respect to a present or former director, executive officer, or employee: (1) any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; (2) any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); (3) being subject to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his or her involvement in any type of business, securities or banking activities; and (4) being found by a court of competent jurisdiction (in a civil action), the SEC or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

 

Audit Committee

 

We do not have a separately designated standing audit committee. The entire board of directors performs the functions of an audit committee, but no written charter governs the actions of the board of directors when performing the functions of that would generally be performed by an audit committee. The board of directors approves the selection of our independent accountants and meets and interacts with the independent accountants to discuss issues related to financial reporting. In addition, the board of directors reviews the scope and results of the audit with the independent accountants, reviews with management and the independent accountants our annual operating results, considers the adequacy of our internal accounting procedures and considers other auditing and accounting matters including fees to be paid to the independent auditor and the performance of the independent auditor.

 

We do not have an audit committee financial expert because of the size of our company and our board of directors at this time. We believe that we do not require an audit committee financial expert at this time because we retain outside consultants who possess these attributes as needed.

 

For the fiscal year ending December 31, 2022, the board of directors:

 

  1.  Reviewed and discussed the audited financial statements with management, and
  2.. Reviewed and discussed the written disclosures and the letter from our independent auditors on the matters relating to the auditor’s independence.

 

Based upon the board of directors’ review and discussion of the matters above, the board of directors authorized inclusion of the audited financial statements for the year ended December 31, 2022 to be included in this Annual Report on Form 10-K and filed with the Securities and Exchange Commission.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

Section 16(a) of the Exchange Act requires our directors and executive officers and persons who beneficially own more than ten percent of a registered class of the Company’s equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other equity securities of the Company. Officers, directors and greater than ten percent beneficial shareholders are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file. To the best of our knowledge based solely on a review of Forms 3, 4, and 5 (and any amendments thereof) received by us during or with respect to the year ended December 31, 2022, all filings were timely made.

 

Code of Ethics

 

We adopted a Code of Ethics for Financial Executives, which include our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. The Code of Ethics was filed as an exhibit to the annual report on Form 10KSB for the fiscal year ended December 31, 2004 and filed with the SEC on April 14, 2005.

 

 22 

 

Item 11. Executive Compensation

 

Compensation Discussion and Analysis

 

Currently, the objective of the cash compensation paid by the company is to provide fair reimbursement for the time spent by our executive officer and independent directors to the extent feasible within the financial constraints faced by our developing business. The stock options granted to our executive officer and to our independent directors are intended to provide these individuals with incentives to pursue the growth and development of the company’s operations and business opportunities. Although the options awarded to our executive and directors are typically exercisable immediately, they also remain valid and exercisable for terms of several years. We believe this provides the proper balance of short-term and long-term incentives to increase the value of the company. Although an immediate increase in share price following the issuance of the options would obviously result in a profit if those options were exercised, the longer exercisable period of the options also provides an incentive to increase value over the long term and gives our executive officer and directors the opportunity to realize gains based on the sustained growth of our operations and revenues.

 

In addition, our sole executive officer holds substantial ownership in the company and is generally motivated by a strong entrepreneurial interest in expanding our operations and revenue base to the best of his ability.

 

Summary Compensation Table

 

The table below summarizes all compensation awarded to, earned by, or paid to our former or current executive officers for the fiscal years ended December 31, 2022 and 2021.

 

SUMMARY COMPENSATION TABLE
Name and principal position     Year       Salary ($)      

Bonus

($)

     

 

Stock

Awards 

($)

     

Option

Awards

($)

     

Non-Equity

Incentive Plan

Compensation

($)

     

Nonqualified

Deferred

Compensation

Earnings ($)

     

All Other

Compensation

($)

     

Total

($)

 
Terry Howlett
CEO & CFO
   

2022

2021

     

180,000

180,000

      —         —         —         —         —         —        

180,0001)

180,000(2)

 
                                                                         

(1) Due to financial constraints, however, the total paid to Mr. Howlett during the fiscal year ended December 31, 2022 was $0.

(2) Due to financial constraints, however, the total salary paid to Mr. Howlett during the fiscal year ended December 31, 2021 was $0.

 

 Narrative Disclosure to the Summary Compensation Table

 

We granted Mr. Howlett the right to convert his accrued compensation of $630,000and $450,000 as of December 31, 2022 and 2021 into our common stock at $0.10 per share at any time until 2028. If exercised, we also agreed to issue one three-year warrant for every two shares converted by Mr. Howlett exercisable at $0.15 per share.

Outstanding Equity Awards at Fiscal Year-End

There were no unexercised options, stock that has not vested, or equity incentive plan awards as of December 31, 2022.

 

The table below summarizes all compensation of our directors as of December 31, 2022.

 

DIRECTOR COMPENSATION
Name

Fees Earned or Paid in Cash

($)

Stock Awards ($)

Option Awards

($)

Non-Equity Incentive Plan Compensation ($)

Non-Qualified Deferred Compensation Earnings

($)

All Other Compensation ($)

Total

($)

David St. James $6,000 - - - - - -

 

 23 

 

Narrative Disclosure to the Director Compensation Table

 

All the fees earned or paid in cash and stock options awards granted to Terry Howlett were earned in connection with his service as an executive officer. Mr. Howlett received no compensation for his service as a member of our board of directors.

 

Mr St. James was paid $6,000 for his services during the year ended December 31, 2022.

 

On September 22, 2018, we granted an option to purchase 2,000 shares of our common stock to Mr. St. James. The options have a strike price of $1.75. The stock options were exercisable upon grant and have a life of 5 years. The stock options were valued at $35,497 using the Black-Scholes option pricing model.

  

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

The following table sets forth, as of March 31, 2023, the beneficial ownership of our common stock by each executive officer and director, by each person known by us to beneficially own more than 5% of our common stock and by the executive officers and directors as a group.

 


Title of class
  Name and address of beneficial owner (1)   Amount of beneficial ownership(2)   Percent of class(3)
Executive Officers & Directors:
Common   Terry Howlett(4)     11,041,001 shares       40.0 %
Common   David St. James(5)     2,000 shares       Less than 1 %
Total of All Directors and Executive Officers:          11,043,001 shares       40.20 %
                     
More Than 5% Beneficial Owners:                    
Doreen McMorran(6)         10,250,510 shares       37.0 %

 

  (1) Except as otherwise indicated, the address of each person named in this table is c/o Skinvisible, Inc., 6320 South Sandhill Road, Suite 10, Las Vegas, Nevada 89120.

 

  (2) As used in this table, "beneficial ownership" means the sole or shared power to vote, or to direct the voting of, a security, or the sole or shared investment power with respect to a security (i.e., the power to dispose of, or to direct the disposition of, a security). In addition, for purposes of this table, a person is deemed, as of any date, to have "beneficial ownership" of any security that such person has the right to acquire within 60 days after such date.

 

  (3)

Except as otherwise indicated, all shares are owned directly and the percentage shown is based on 27,741,990 shares of common stock issued and outstanding and dilutive shares on March 31, 2023.

 

  (4)

Includes 154,466 shares held in his name as indicated on our shareholder list, and 10,886,535, shares of common stock held in derivative securities.

 

  (5) Includes an option to purchase 2,000 shares of common stock at $0.035 per share.

 

  (6) Includes 36,000 shares held in her name as indicated on our shareholder list, and 10,214,510 shares of common stock held in derivative securities.

 

 24 

 

Item 13. Certain Relationships and Related Transactions, and Director Independence

 

Aside from that which follows and in “Executive Compensation,” none of our directors or executive officers, nor any proposed nominee for election as a director, nor any person who beneficially owns, directly or indirectly, shares carrying more than 5% of the voting rights attached to all of our outstanding shares, nor any members of the immediate family (including spouse, parents, children, siblings, and in-laws) of any of the foregoing persons has any material interest, direct or indirect, in any transaction for the last two fiscal years or in any presently proposed transaction which, in either case, has or will materially affect us.

 

On February 3, 2020, we entered into a License Agreement with Ovation Science, pursuant to which the Company granted to Ovation Science Inc. a license for the manufacture and distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay to Skinvisible a percentage on all net sales on the licensed products subject to adjustment in certain situations plus a license fee payable in year 3 of the agreement if it chooses to continue the license.

 

 On June 10, 2020, Ovation Science Inc. paid the Company the fee otherwise due in year 3 and in exchange the Company extended the term of Ovation’s license to 6-years and granted Ovation additional rights to its hand sanitizer products and assigned Canadian Identification Numbers 02310589 and 02355558, all DermSafe Trademarks, DermSafe clinical data and the right to patent DermSafe where not currently patented. In exchange for these rights Ovation paid a $100,000 license fee. The Company completed the required assignments during the year ending December 31, 2021 and recognized $100,000 in revenue.

 

 The Company earned $0 and $2,458 in royalties under the license agreement during the years ending December 31, 2022 and 2021, respectively.

 

The Company sold polymer products to Ovation Science Inc and earned $0 and $2,458 as of December 31, 2022 and 2021, respectively.  

 

During the year ended December 31, 2022, $0 in advances were repaid to Mr. Howlett.

 

During the year ended December 31, 2022, $25,200 in advances were repaid to Ms. McMorran.

 

As of December 31, 2022, $27,299 and $52,499 in advances remained due to Mr. Howlett and Ms. McMorran, respectively, and all other related party notes have been extinguished or re-negotiated as convertible notes.

 

The following table details the notes that are outstanding for Terry Howlett and Doreen McMorran.

Noteholder Date of Note Interest Maturity Outstanding Principal as of December 31, 2022
Terry Howlett June 30, 2019 10% December 31, 2024 $2,108,519
Terry Howlett June 30, 2019 10% December 31, 2024 $68,788
        Accrued Interest as of December 31, 2022
Terry Howlett       $765,338.19

 

Noteholder Date of Note Interest Maturity Outstanding Principal as of December 31, 2022
Doreen McMorran June 30, 2019 10% December 31, 2024 $2,004,502
Doreen McMorran June 30, 2019 10% December 31, 2024 $38,400
        Accrued Interest as of December 31, 2022
Doreen McMorran       $720,553.15

 

Item 14. Principal Accounting Fees and Services

 

Below is the table of Audit Fees (amounts in US$) billed by our auditor in connection with the audit of the Company’s annual financial statements for the years ended:

 

Financial Statements for the
Year Ended December 31
  Audit Services   Audit Related Fees   Tax Fees   Other Fees
2021     $ 31,124      $ 0     $ 0     $ 0  
2022     $ 33,500     $ 0     $ 0     $ 0  

  

 25 

 

PART IV

 

Item 15. Exhibits, Financial Statements Schedules

 

(a) Financial Statements and Schedules

 

The following financial statements and schedules listed below are included in this Form 10-K.

 

Financial Statements (See Item 8)

 

(b) Exhibits

 

Exhibit Number Description
2.1 Agreement and Plan of Merger(4)
2.2 Termination and Release Agreement(6)
3.1 Articles of Incorporation, as amended (1)
3.2 Bylaws, as amended (1)
3.3 Certificate of Amendment(2)
3.4 Certificate of Change(5)
14.1 Code of Ethics (3)
31.1 Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2 Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

  1 Incorporated by reference to the Registration Statement on Form 10SB12G filed on April; 30, 1999.
  2 Incorporated by reference to the Report on Form 8-K filed on September 12, 2008.
  3 Incorporated by reference to Current report on Form 10-KSB filed with the Securities and Exchange Commission on April 14, 2005.
  4 Incorporated by reference to the Report on Form 8-K filed on March 29, 2018
  5 Incorporated by reference to the Report on Form 8-K filed on January 22, 2019
  6 Incorporated by reference to the Report on Form 8-K filed on October 22, 2019

Item 16. Form 10-K Summary

 

None.

 

 26 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

  Skinvisible, Inc.
   
By: /s/ Terry Howlett
 

Terry Howlett

President, Chief Executive Officer, Principal Executive Officer,

Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Director

 

  March 29, 2023

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

By: /s/ Terry Howlett
  Terry Howlett
 

President, Chief Executive Officer, Principal Executive Officer,

Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Director

 

  March 29, 2023

 

 

By: /s/ David St. James
  David St. James
  Director
  March 29, 2023

 

 27 

GRAPHIC 2 image_001.jpg GRAPHIC begin 644 image_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# H'!P@'!@H(" @+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#V:BBD)H * M*;NYZ4Z@ HHI,^U "T4@;-&: N+2TT'-.H ***1C@$^E !14#WD,3;998T., MX9@/YTW^T+7_ )^8?^_@II-DN45U+-%5OM]I_P _,7_?P4?;[7_GXA_[^"BS M#GCW+-%5O[0M!UN8?^_@_P :/[1L_P#GYA_[^#_&BS[!SQ[EFBJW]H6G:YA_ M[^#_ !H_M"T_Y^8O^_@_QHL^P<\>Y9HJM_:%I_S\1?\ ?P?XT?;[7_GXA_[^ M"BS#GCW+5)5<7]IC_CYB_P"_@I/[0M?^?F'_ +^"BS#GCW+-%5OM]K_S\0_] M_!1_:%IWN8?^_@HLPYX]RS15?[?:?\_$7_?8H^WV@ZW,0_[:"BS#GCW+%%5O M[0M/^?F'_OX*/[0M>US#_P!_!19ASQ[EJBJO]H6O_/S#_P!_!2_VA:?\_,/_ M '\%%F'/'N6:2J_]H6G_ #\Q?]_!2?VA:_\ /Q%_W\%%F+GCW+-%,,J^7YF0 M5QG.>,5 -0MC_P MXO\ OX*+,;DD6J6JO]H6G>YA_P"_@H_M"T_Y^8?^_@HL MPYX]RS15?[?:?\_,/_?P4Y+N&4D12(^.NU@<468*2?4FHJN][!&VV26-#Z,X M!I/[0M>UQ#_W\%%F'/'N6:*K?;[7_GXA_P"_@H^WVO\ S\0_]_!19ASQ[EFB MJWV^U_Y^(?\ OX*/M]K_ ,_$/_?P468<\>Y9HJ!+N"5MJ2QL<9P'!-07>K6U MD8UF;YY/NHH+,?P'-%F',B]2UGV>L6M](\<+?/']]#D,OU!YJ_FD--,6BDHH M&%17#^7&7S@*,D^U2U4U7C3+D^D3?RII7=B9.T6SD)_%^HSS[+-4568*@*[F M;FK/VOQ?_P ^X/\ VS7_ !K"T0'^V;(?0YJMVV< MC]K\7_\ /L/^_:_XTGVSQA_S[C_OVO\ C788]J7 KF]IY'3[%]SGM"N]5^0#YL^H)[4WQ3JM_IC6S6T_ZZ'^5512G446*K>%-V9I>'=1N=0TY9[EE,F\J=JX'Y5M5SO@S_D"#_KJW M]*Z'IUJ*L5&;2-:+O!-BTAZ5%-/%"I>1PB@9)/052@U[3+F988+M))&Z*H)) M_2HL[%N21S7C95.HVY*@D1'J/>LBST2]U"%IK6WC=%8J26 Y_P FM?QK_P ? M]O\ ]]6:9DO"$D:-T4 M%201CN*;Y4?]Q?RJ25G,SF08D+'<#ZYY_6IY-,U".(RR66G]Q?RJ\NC:HPR-/GQ_NTHT75L_\ (/G_ "%+VV'7 M8?)5[%#RX_[B_E1YRF6-1DL5Z"JIY (JH>RG\-B9< M\=Q/+3^XOY4&-,?<7\J4&EK7V<.Q/.^XT1I_<'Y5);V3W=PL$$2M(_W0<#]: M?!:W%T6%O"\I49(4=*EM%O[?40EK$WVM,D)@$CCGBN2M*FHM1MPR] MTNXL&1;N%$,@)4 ANF/3ZU6\M/[B_E6CJ\NI2O#_ &E&T;*#Y>5V^F?Z522* M2=PD*/(W]U!DTJ#C[)2FD.I?G:B1&-/[B_\ ?(H$:?W%_*KXT752 ?[/G_(4 M[^QM6_Z!\_Y#_&K]OA_(7)5[&?Y2?W%_*CRU[*OY5?\ [&U7_H'S?D*@N;*[ MLU!N;=X@QP-PZGTIJK0D[*Q,HU5JQUCIESJ)<6L*,8\;]S 8J&XLY+:=[>XC M59(^& P1R*NZ0^JQ>8VF1,X8XD(4''YU6O6N9+V5[Q2MP<;P1CG [?2N5-NJ MXNUC;5131V]A+Y_A6-NWV4C'T7']*\_6--J_(O0=J[W21_Q1Z?\ 7LW]:XZ' M2=2DC5DL)R"H(RN*Y\)*G&6G]Q?RJ]_8NJ_\^$W MY"C^QM5!R;";\J]'VV'\CBY*I1*+C[H_*NB\%874+A0 -T0.1]:P9HI;=RD\ M;Q/C.UQ@UO>#?^0M-_UQ_K66+4)4'*)KAW*-5*1!XO1?[=/RCF)>WUK$9$S] MT?E6YXNXUT_]6G]U?RI?+ M3^XOY5>&BZH1G[!-^0I1HNK9_P"0?/\ D/\ &M?;8==C-0J]F4/*C_N+^5'E M1_\ /-?RJ_\ V-JHZV$WY#_&JTT$]M)LN(9(7]'7&?I51J4).RL)QJK5FEX5 M 77$(4?ZMN@]JT-0CDDU.^B/S7$DEOY0Y.8N,\#G&>M4/"G.O(/^F;5VM[IE MMJ&S[1"'*?=;)5E/L1R*\?%VC6T/3PJ>#[6:=GMYI("Q.5V[E_^M4)\##_H(-_WZ_\ KUZ,JN'JVUI_UT/\J(TO9XE) ZKJT&V6_!QQ MH8_ZZM_2K^J:U;:9#NG;YR/EC7EF^@KD=-UZ6PTI;.TA,MRSL<8SC/MW-9U[ M%?07RR7Z$S-ASYOS!O;Z=N*F5'FJRN$:_+25C9QJ?BN4.W^C6(/ ['_XH_H* MZC3=(M-,B MT^8_>=N6;ZFHM#U&VU*P62-0K#Y7C_N'T^GI6IVP.U77_ %U?^9KMM<_Y%>7_ *YI_,5K72?LS.CIS'(C6=448%_,/QI? M[:U3_G_F_.J/-+6/[)! M;B*<88B*BC MMI3RVSCF-L9]1V/Y5-H]__ M &;J,5P?]6?DDY_A)_IUK?\ %FGB6U348AEHP ^!U4]_PIQOAZ^NS$[5Z-^J M.3I20!D].])^?XUH:)IYU+441@3%'\\A[8[#\?\ &O5JU5"',<-.'/*QI6A. MB>&VN2/]*NSE >W'RY^@YJGX:R=?A+,S%PVXL8J5J+G+=G9SWJ1BMD:'C?(N+,#IM;^8_PJYX M0MD727N0OSO(VX]R!VJIXW_X^;+_ '7_ *5:\'7:-826I:JG(+*,@_6NH/@NUZ"\G!^B_X5S^LZ-+I$J?O/-AD)",1@Y]#_.MZ57# M2FDEJ8U:5:,6WL:_@G[]XO;"'GUY']*RO$0QX@N_JO\ Z"*U?!'^LN_]U?ZU ME>(O^1@N_JO_ *"*RCIBI6-9?P$=5HLAC\)12#&4@8C/MFN/&N:JQW?;I1GG M X%==I7_ ")R_P#7L_\ 6N#3[H^@I8*G&=22DAXFR-@]&P0:HTE>A4PU)0=D<<*TN9:G:>+;1&TA;C&7BD4CCUX/X#.=4F/_3'/ZUL^*_\ D77_ -]/_0A6/X+_ .0I/_UQ_K7E0;^K2/0G_&BR M'Q:Q/%O_ "'C_P!&( M8U&2T! 'J<4JG\" J?\ &D<>-;U5ADW\N3SQ2_VWJO\ S_S?I4R^&-8V@?9E MSC_GH*7_ (1G5O\ GW7_ +^"NZ+PMM3C:KWN5SKFJJ0POI21V/2NHUN!;KPS M]JDQYH190<=#QG%<\WAG5RI MU)_ZZ"NHU:,P>%)8WQN2WVG\A7)7=+VD?9G M50Y^27.#OY35B_\)???] EO_'O\*J:CX@O=1LY;4Z: MZ"5=I;:QP/RJX4FI)F=2M%QLBAX=_P"0_9CON/\ Z":W?&Y'V:T_ZZ'^54_# M&CW1U!;NXB:%(P2BN,%B1U]L"K7C99&2SC2-WY9B54G'0=OK73.<7B$TSEA" M2H--$G@^SA.GM<^2ID:0@OWQQ6OK&E0ZK9F&7Y6'*2#JAK.\'%UTAD>-D(F8 M8((]*Z(KGO7)5F_:MIG90@G22:/-8IKWP_JA.T"1.'7^&1:[[3]0M]0M4N(6 M)#<8/4'N#5/7]$BU.W&/DGC&8Y/Z'VKDM+N=0T34"S6TQC)VRQ;"<^X]_>MI MC-#QK_ ,?]M_US/\ZT?!7_ "")/^N[?R%97BJ4WMQ:3VZ. MZ/$2"$/K^E;'@^&2'1F\Q&4M,Q 88/8?TJY27U91\R(Q?MW+H<;?<7ET?^FK M_P S7;:Y_P BO+_US7^8KCM2M+A=1NT$$C9E?&$)!R3WKM=8B=O#<\:J681# M@#)XQVJZLXOV?D32BUS' >_K13U@G(_U$OX1FCR+C_GA+_W[->W&M3MN>8Z< M[[#K3_C]M_\ KLG_ *$*ZSQG&O\ 9L4A49\T+GOC!XKF+.UN#?6P\B49F3JA M'<5UOBZ)YM(0(I8K,I(4$GN/ZUY.*G%XB+3.^A&2HR31Q!Q@YZ5V/AJ]74M' M>SN"&>(;&R?O(>A_I^%A]OKS7 M1C>2I"Z>J,<-S0E9K1E;4+)M-O);1\_NS\I]5/0UNL3H/AWR^EY=GD^F?\!6 M[?:/;:C>VMZQ'[GJ.SCJ*Y#69[C4M3>98)3%&2D?[L]/7\:Y(5O;\L);(Z)T M?8W<49H&!BM;PS_R'[;Z-_(UFF"?_GWF_P"_9K5\,P3?V["S1.JJK,25([?_ M %Z[\3.'L6DSDHPFZB;1?\;D?:++_=?^E,_G7+AJU.%!*9M7I3G6]TSAJ6H8_X_ MKC_OZW^-*-2U ?\ +]U]'_W[/^-'_"$7(_Y?H_\ OV?\ M:?UC"_RC]EB%U,0:CJ!E4_;Y\@C&9"1U[@FNI\8(#HL+$?1/ZUE^(SCQ#>?5?_016QX+ADC^V.Z,F2H&X$9K)\2V\_\ ;UTRPNP; M:00I(^Z/\*N,X_6&PE"7L$K'2Z2?^*/3_KV;^M<(I^4?05Z!8PBU\*Q),&"_ M9_GP,D9'I^-82>"YG&4U",KU!\L].W>IPM>-*;;'B*,IQC9'.T=ZZ3_A"+G_ M )_H_P#OV?\ &G)X)E#!I+Y-@.6Q&>1^==T\=2E%HY886HG=HT_%3 ^'7Y_B M3^8K'\&?\A6?_KC_ %JSXHOUFLTL;='F.\,Y5"0 .@SC&:@\'12Q:C.[Q,@\ MH#+*0#S7GQ:6'DCLDG[:)6\7';K;9_YY+_6NBTPD>%82K$%8#R.QK"\60ROK M".(W(:(HIU)0!&4'I2[%]*?11=D\B&;!Z4;!Z4^BB[#E0T1H&W;1GU[T, MH;J,TZB@=D,"*"#MZ4^BEH!*PQE!INQ1SMYZ=*EI*/0&DR,1H,_*.:< !T%. MHH860S8,YQ1L7&-M/HH"R&A%QTI#&/04^B@.5=AFQ3QM%&T>E/HH"R&%!CH* M0(.ZU)11J'*NPS8I_AI!$H.0H!-24M -7W&;!Z4FQ<_=&:DI* LB,HH'"BE" M@#IUI]% 6&T8]:=10,:5'I3?+&?NC\JDHH%8:%7TZ4A5?[HI]%&H[(;CMBD" M!>@ I]% #<4#D8(IU%*PAFP>E&Q?[HI]%/4$D,**>JBC:H& !^5/HHU"R&@< M44ZB@8@II12<[1FGT4"L-"C.<4X44M )6"BBB@84444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 %10!__]D! end GRAPHIC 3 image_002.jpg GRAPHIC begin 644 image_002.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# H'!P@'!@H(" @+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#V:BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKA_BKK>H:1H- ME%I=W):W=[?1PK)'U YS_2@#N**\P^+?BS4_"_\ 8D6FWDD4K,TD^W_EJJ[> M#[')K1\2^([NYU_P=::3>/!%JDOGS>6?OQ *<'VQF@#OJ*X8ZQJ5O\9AI$EW M(=/N=.\R. GY0XZD?]\G\Z1]9U'6OBLND:?>20Z;I$'F7PC(Q+(W13^8_(T M=U17!>!];U'6/$?BNYN+R6:QM+KR;:$_=3&[./R%I'3(YH ]IHKB/%7B+4]/^%GKB@#OZ*\D^R_$CPI=:=J MUYJ6,:E_+!ZXX[>HQS7HOB;6XO#WAR]U:7&+>(LBG^)SPH_$D4 M:U%>:?";Q%K6I2ZQ:>(;N26Y@,4BK+C**X)P/TH\<:CK^H>/-+\-^'M9;3C+ M:M-*ZC([D9_!?UH ]+HKR_P]J/BKP_\ $2V\-:[K2:O!>VS2JP7F,@$@],C[ MI_.FZ]/XJ\1?$N^T+P_K[Z;!8VB._&5W''MU^8?E0!ZE17*>$- \3Z1=7,GB M#Q%_:L;?$!UU'XA^#]%^\%N#DUQGB2RT;1?%EEXPU*2[: M95^RQI'@HG#)-/3Q/\6UTB50T-MHTN[/0,^0#_ ./ MUS/PTN+K5?'6E6-Y$0WAZRGA)/KN('Y;L?A7HNB#PU-XHO?$=GK"S7=]$L31 M22!0BC' ! /85=T;P=I>D>)-1\06;R&?41^\0D%%YR=N!W-#36XE)2V9R'Q' MU&/PU\0?#GB&8'RD@GC? ZX!P/S:M3X:V$NF>$;KQ#J'_'[JK/?3,W7;R5'T MQD_C6UXO\$Z;XTBM(]1EGC6UD+KY) +9QD'(/'%:U[IT%SHTVF;C!!) 8,QD M HI&./PI%'GGPRU"WT+X<:CXDOED,!])M"A\/:Y(;)X4@KC-;&I>'I?%M_IEY9 B?*A/'7/)Z#I5GQ'X6T/7-*;3]4>25MV]'B.&C;U'_UZKDMIU!2N M&K>.+?3M!_@:XKXJZK=7&J:;X=2VN+\(PO+RW@ MRS,H/RKP#CN?Q%;_ (4\!Z=X;OFOK/[3>WI7:MQ62N+>4>*_BQK*Z9K,NFR:=:)&D\8.2< ;>",#)->@-X9T[_A+(_$C7 MLINDM_LY1<;&7W[YHT;PSI>C:OJFIPSW$L^IR!Y?,(PN"3@8'3FI&<=\(]*M M+FXU#6-1N;FXU^WF:TG-P^[RQ_L]^<8R?0UF:7X2A\=^+O$^IRZO=6"17WDH M;=@-X&1S],"O1M*\,:=I'B'4M9M)[A9-2P983CRPPYR!C.>OYUR[_!30)9I) MO[6U,-*Y=L2*,DG/]VI8SK/"'A>'PKI\MI#J%S?^;+YAEN&W$< 8^G%=!6)X M6\,6GA/2?[-LYIIHS(TA>9@6)./3Z5MTAA1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %DV]HFH:7'J%M<.RNKXRN!U&>]:4E>:,:[M3>IQHT+PCJ?S:;K[6;GI#>) MT_'C^=6HO ^L)S8:U:RKV,5PR_RJ 6?@750&M[ZYTF1OX)5W*/SS_.I(_ T4 MGS:?XCL)1VRVT_H:]'FMO)KU1Y#@GM%/T=B_%X3\6 8;4,C_ *^VJPGA'4SS M>:I @[[I6;^=4HO!.JIUU:T(]IVJVGA 1\W>M6BCO\V?YFHE/^\ON-:=-_R/ MYLMQZ)HEES=ZNLC#JL6/Z9JW%J>D69 L;$R/V>3_ .OS5*+3O#EGS-J;W)'\ M,0_PJY#J^GVYV:;IHWGH\G7_ !K)WEW?X'5&R[+\2[&VK:ERP\B(_P# 1C^9 MJ8)8V0^9OM$@[#H*Y[3O%(U^_ALVDN;<7)<0/+ T<4Q7.X*W\1X/Y5N7%SI. MC1P-,S7#S.R1B-=Y+*I8@ >RFL7)+K]QTQ3?_!+"W-YZ?-HOVB2UEBO?LCR8 M*-Y)F5-QC#]ST./ZULZAING0:Q>>(]7DMY;:"T2-4EB#>3M)8GG/)R.GI7(Z M?HH\1+=V+7\T$5C,\\5I<6;13@3-O+-D_-\NY5QZ\U/,QV1T:^-=&@TNUN;O MSO.F#!XX868JZL$88ZXWD >M+;^/=!F$I(O8!%&S'SK9EW%6"LB^K!B!@>M8 M^FZ) $O-?OK@V,;:C_:'DW ^>*V1BP!4'YFYNG=/(-N0\)0@-Y@_A R. M:Z*N5\+^&8=#OOM"WEM*SVWE^7"@4!BY9R!D\?='K\O-=32&+1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %0W-K;WD1BN8(YHSU610P_6IJ M* :N7X5@',&J\=O,A_P->AT5O'$58[,Y M9X2C/5Q/.X_AI>H>=2@(_P!QJT+?X?;#^^U '_ZI=6UT\4< 91T M.TG-0?VU>_\ /LO_ 'PU-XFJ^HHX.C'9"6W@_38,&1I9B/[S8'Z5?GM(K#3+ ME["T7SEA8QK&OS,V#@?G5'^VKW_GV7_OAJ/[:O?^?9?^^&K%SE+=G1&$8[(X MF?3M>U'PEI]E8:5?V+Z/:EV>9 LDL[+M(C&>.PJK#X8U8HJ6^G7*6TS MDJIMQ!LSY<9;8"=I*[R><\9[UWDOB&Y@V&6!5\QPB_(W+'H*D_MJ]_Y]E_[X M-26<%?\ AK6_)W2VEQ]CLM0D@AABA\]GMR[.7\O(W!F*+C/1:)_##V?AO4[W M5+1DFT^QC6P,V!M8LTK*@!P#DA>/I7>_VU>_\^R_]\-4%U>O?+&MWIT,XBD$ MB"2(D*XZ$>XH S[C2[JW\$2_;-,DU&XU*83ZG!$Q\P!R"VS'.4&T ?[-<[<6 MFM V/V>6\$MQJ#6]@=1(^U1P/"5=VQR0IR1GG\Z[G^VKW_GV7_OAJT+6W@N9 M(=2GM8A>",QB3;\RJ3D@'L* /+9_"]V9-1@AT"Z>W"F(^="#(@WHN(W!_>J4 M4M@CY?K0?"VLW-U=@V-U'(SR02,+<(OER.$"J^[+H(^> N/6O7Z,4 >?:!X M5-AXHM;R'239QK=7DA<# 6( )$GT/+8_&O0:*6@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BD+!>M)O'O0 ZBF[Q[T;Q M0 I.*K_:@7=5AE?8=I*@8S^=3%Q[U% -C2D_QR;A],"@0?:6_P"?:;\A_C1] MI;_GVF_(?XU-O'I1O'I0&I#]I;_GVF_(?XT?:6_Y]IOR'^-3;QZ4;ER!ZT!J M0_:6_P"?:;\A_C1]I;_GVF_(?XU/2%@#B@-2'[2W_/M-^0_QH^TM_P ^TWY# M_&IMX]*3>/2@-2+[2W_/M-^0_P ::]YY<;.UM,%4$DX'3\ZL;UJ*Y'FVTL:_ M>="HSZD4!J0QWYEC61+.X*N P.%Y!_&G?;'_ .?*Y_)?\:=:X@M8(7(#K&JD M9ZD#G%3[Q0%F5OMC_P#/E<_DO^-'VQ_^?*Y_)?\ &K.\4;Q0%F5OMC_\^5S^ M2_XT?;'_ .?*Y_)?\:LA@3@4Z@+,J?:W_P"?&X_)?\:/M;?\^-Q^2_XU9WKD MCTHWB@+,K?:V_P"?&X_)?\:/M;?\^-Q^2_XU9WBC>* LS$UB>27["%LIQMO8 MVY"\@9]ZT?M;=?L5Q^2_XT7D;3-;E,?NY@[9] #_ (U9#"FWH))W*_VMO^?& MX_)?\:/M;?\ /C*-XI#LRK]K;_ )\;C\E_QI?MC_\ /E<_DO\ MC5G>*4$,,B@+,J_;'_Y\KG\E_P :/MC_ //E<_DO^-6C@#)I-XH"S*WVQ_\ MGRN?R7_&C[8__/E<_DO^-6=XIIE1>IQ]: LR#[8__/E<_DO^-(+XF3RS:W ; M&<$+T_.K.\>E1$'[6LO\(0K^.10%F'VEO^?:;\A_C1]I;_GVF_(?XU(TJ(I9 MB% &23P!0LJ.H93D'H1R#0&I']I;_GVF_(?XT?:6_P"?:;\A_C4V\>E)O6@- M2+[2W_/M-^0_QH^TM_S[3?D/\:GXH) ZT!J0?:6_Y]IOR'^-'VEO^?:;\A_C M4V\>E&\4!J0_:6_Y]IOR'^-'VEO^?:;\A_C4V]:-X]* U(K>Z2Y#[593&Y1@ MPP0?\FIZIV<;0O] QU%-WCWHWCWH =13=XSCUIU !1 M110 4444 13G&P_[5,W#UHNSMB!_VJJ>;[T 6]P]:S-8\2:7H)A&HSO&9]Q0 M)$TG"]2=H. /4U8\VL37=!37=3L)IY66UMXYDF2.1D:0. ,9';CD4@.B^U6_ ME>:9XQ&%WEBX "^OTIPFB8 K(A!&00PY'K]*X6Y\&S76M7US)):&VN8)857! MSM9 J!ATPI7.SA_T988UBD=1!A&4JHQRI)SS[]:8'H3W5O% MM\R>)-S;%W.!EO0>_M4FX>M>=P^ !;P1(BV4OE2VLPCE#%6>--LA]BW7/M7< M^;[T 6]P]:-P+H/]JJGF^]/A?=.@]Z -"H9"!)SZ5-5.[?;(ON* )-P]:X!K MG7[34];73GD@0W%SQ.>GX5HZUXMGTK7$T^.SBN%*1-CS") M7,CE<(,8.,9.3TJ6'Q_X>GNVMH]08NDPA+&-@N22 <]-N01GUH S[G6/%<<4 M\$4N9+?SG\[[%GS0L2.J@=!\S%<]\>M4+[Q1XRM8S&L1,]O#]ND#W">9&#$W YQGTS@D>M2V7C?1K\I]GGGS))'& MF^!D+&3.PC/\)P>?:@+'(:Q>>(=5U&4:A9W >U@O%$$=JRH@:(;")!]XMSQV MJ]-KWBJ:[OM-M([NWABL9/*?[+\R.J*5VMC!SSW)^E='_P )KHJWME9M>.LM M\,P@H<.$_MB_M;F&Y2&"X%M;JEJ[2.X7QV\^Y. M"NU?L[YF#-M#(/XE)XR*M:3XHT[6I6BLSTW5--;4;*X\VV0L"^TKRO48.*CU MF.XN;"]M;258IYD9$=^BYX)_+-3J#1K "OS9?ID9X%7UN[=VD5)XV:$XD !KVUOM-GDNK6860MOG;?OC$0(94[8;.>:LW7A"9[_ %.X@6Q>*]O8 M[HPR!@)0JX,\TN4R#SMWEN"&!0$<@ -@' MVJA?^&-8U#6!>RW=DJRS6\\RKOR&B5EVKZ@[N_I0!W7G1DX$BDDX&&'-'G1X MSYB8/?<,5P5EX"CM]/MH': 3P64T0F4,2L[MD2CW XJBGPYE>&**=[41QQS MQ"1V7S&C"JXSC'S#=C^9H ]*6YADD>-)HW>,X=58$I]1VJ:#[A_WC7)>'] ; M1=3O;HBV;[7%"&E0$2%U4*V?4$C.?>NKM#F 'U)H DD_U3?0U$&&!SVJ63_5 M-]#6>)>.M %OW^U7%RB0$D)%)M5\D$[O7ICZ$U%J^K-ID%O* ML0D\ZZB@(+8P'."?PK.C\>:#+,D0GN%+LH5GMG53N.%.2,8)XSZT Y4'D=N?2@#(O+[6]9\!7EQJ%JT3W%PB+%Y)8V\:L SL@ MY<;@3@=0:T?A_>7#Z3-9W&G2V2V[@QF1&7SM_P S.H(&%+9PO88S3[WQYH&G ML#@#2'W1 M]*9,<*#[T\?=%0W9VPY]Q0!F:_K!T72FNTA\^4R)%%&6VAG=@JY/89/-49_% M']C>5;:W'OOF4R2KI\;21Q1;MHD;/*KGBKFHV=IJUC)8WT0FMY0-RY(Z'((( MZ$&LZ7PMI$_EF9;F1T78TCW+EI$R#M:=:W1MTL[^X=;Q+1O M+AP-S'&1D\C(Q6;KGCJ^TO7]6L(K.*6'3K83 A)&>0E"W4#:H!'XFN9(93--(DAD\]MRE"67;SP 2>*DNO#NF7E[=WXBC@CA18UM"KS2NNXEH7L<$:.[V\&44M@A2Q/#88'%2S>'=)G4AHI%8LCATE*LI1-BD'M\O%- MN/#.D77GK-%,4N8PDT8G8*^ &(S]X #YO:F Y/%]M#/>)>I)"("[1@(=S*J M(Q4_[?S]!5JR\4Z;?ZU-I$/GK[$?VBW:0Q7* MW2EI"3Y@4*"3WX XJS;Z58VFI3:A LBS3LS./-)3:ME&D%Y]C^T3;PN0N3(^. M@/08[FMOS?I1YOTH Y4^-=8CFGNFL,Q?V,X-=%YQ]:/-'MQT]J .9T_Q7J T^WNKA MDEEEM+?S)'W+#$[LP9V '&,\WZ4>;]*8%TRX)&>:O>;69XALIM5T:2U@9?,\Q) KG"R;6#;#['&* (F7PCM.H M"[MXXW1;=G2>]9LFD MZA>+KEY);16TVII$D=H) P79CYF8<9/]*MPVE]8^)KV]2UBNX-0,69#(%:W" M#!&".1W&* +\%AH$$L1"T403ZK]L%P)UY3@8V]<\5'/IGBA=/>.VO9? M-:&$OON-Q:0,=X!/3*X]!Q1TN'4Z./PSHT31L+>1C#L\K?,S>6%;WAU&O )'7'2K M_FT ;FEMO\P^F*T*R=#;]6%8;=K$X.<9^[WK=U*3;J$H]ZK>;0!A/XJU*W242PVH6.\^Q_:9-X12JY, MDF.@/0 =S4-QXGO;Z2PMS&EIYLEM(PRX>0,_S;./N@#G/K71^;]*/-^E'4#F MY?'EPH(CLX6=8QYI);;;N92A+X&=H !/?FIEU[4IQX@1KNV(M[,2VGD*P89C MSN4GJ,_K6]YOTH\WZ4 O3/?K70^;QCC\J/-^E'4.A=,N">:UK YM$/U MKF_-KHM,.;",^U %B3_5-]#6$)JW9/\ 5/\ [IKE?-]Z )KN"WOXXX[E"ZQR MK*H!QAE.0:Q_L'AFXN3IJRQO:62QB5U"!FC"A\XR#VZXI :6G^#M-M[*WCOD:ZN80H,WF, -K[U"C/ SS MCO5U]+T:74I!(OF7#K)*87D8JHD^5V"]!NZ9KGKG3=?6[A2SN9A'MAQ.]X3Y M)'^MW(?O[JBM=,\0PRS74A+7*Q(@3<%9=YQ_L40O]_ Z#.*PH[;6Y983> M([QR>:)$2\VB#<^5)Q]\!>,5%I-AK=C-I$)C*6MM"8K@&ZW+P3A@.I)XX/ ] MJ8':^=2B7)'UJEYM*DO[Q?J*0'5#H*K:@<6C'T(JR.@JGJQQI[GW% &9YU'G M53\VCS: +HER0*XA_&.JK_:7[RV/E1S^2&MV7RW5PB#/_+3<3VZ'K75>;[U1 MFTK3+B,1S643H-^%(X^PR:F;Z* ^9!DP*[8VR*,# M>,'@=L5OZ#JUS?Q7<=YY)GLKIK9Y(,A)2,'< >G7D53'A_15BDC73X@LI5GP M6RY!R"3G)(]:NVD%M86RVUI D$*DD(@P,GJ?<^] &GYU'G53\VCS: -.RDW7 M:"MFN=TN3=J$8^M=%0 4444 %%%% $-S;I=0F*3.T^E4O[!M/63_ +ZK3HH MS/[!M/5_^^J/[!M/5_\ OJM.B@#,_L&T]7_[ZH_L&T]7_P"^JTZ* ,S^P;3U M?_OJC^P;3U?_ +ZK3HH S/[!M/5_^^JEM=*M[2;S8]Q;&.35ZB@ JK>:?#>E M3+N^7I@U:HH S/[!M/5_^^J/[!M/5_\ OJM.B@#,_L&T]9/^^J/[!M/5_P#O MJM.B@#+_ +!M/63_ +ZI?[!M/5_^^JTZ* ,S^P;3U?\ [ZH_L&T]7_[ZK3HH M K6=C%9*PBS\QRK_ /?5:E% &9_8-IZR?]]4G]@VGJ__ 'U6I10! MF?V#:>LG_?5']@VGJ_\ WU6G10!F?V#:>K_]]4JZ':*X;+Y!SUK2HH 05'<6 MZ7,+129VMZ5+10!F?V#:>K_]]4?V#:>K_P#?5:=% &9_8-IZO_WU1_8-IZO_ M -]5IT4 9G]@VGJ__?5']@VGJ_\ WU6G10!F?V#:>K_]]4?V#:>K_P#?5:=% M %&VTFWM9A+'N+#IDU>HHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH %HH __]D! end GRAPHIC 4 image_004.jpg GRAPHIC begin 644 image_004.jpg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ex31_1.htm
CERTIFICATIONS

 

I, Terry Howlett, certify that;

 

1.   I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2022 of Skinvisible, Inc. (the “registrant”);

 

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.   The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.   The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 29, 2023

 

/s/ Terry Howlett

By: Terry Howlett

Title: Chief Executive Officer

EX-31.2 6 ex31_2.htm
CERTIFICATIONS

 

I, Terry Howlet, certify that;

 

1.   I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2022 of Skinvisible, Inc. (the “registrant”);

 

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.   The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.   The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 29, 2023

 

/s/ Terry Howlet

By: Terry Howlet

Title: Chief Financial Officer

EX-32.1 7 ex32_1.htm

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND

CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Skinvisible, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (the “Report”), I, Terry Howlett, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

 

By: /s/ Terry Howlett
Name: Terry Howlett
Title: Principal Executive Officer, Principal Financial Officer and Director
Date: March 29, 2023

 

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EX-101.SCH 8 skvi-20221231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (AUDITED) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (AUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (AUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (AUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (AUDITED) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 1. DESCRIPTION OF BUSINESS AND HISTORY link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 2. BASIS OF PRESENTATION AND GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 3. SUMMARY OF SIGNIFICANT POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 4. RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 5. INTANGIBLE AND OTHER ASSETS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 6. NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 7. CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 8. COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 9. INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 10. STOCK OPTIONS AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 11. STOCKHOLDERS’ DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 12. SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 1. DESCRIPTION OF BUSINESS AND HISTORY (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 2. BASIS OF PRESENTATION AND GOING CONCERN (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 3. SUMMARY OF SIGNIFICANT POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 4. RELATED PARTY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 7. CONVERTIBLE NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 9. INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 10. STOCK OPTIONS AND WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 1. DESCRIPTION OF BUSINESS AND HISTORY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 2. BASIS OF PRESENTATION AND GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 3. SUMMARY OF SIGNIFICANT POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 4. RELATED PARTY TRANSACTIONS - Schedule of Convertible Notes Payable Related Party (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 4. RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 5. INTANGIBLE AND OTHER ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 7. CONVERTIBLE NOTES PAYABLE - Schedule of Convertible Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - 6. NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - 8. COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 9. INCOME TAXES - Deferred Tax Assrts and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 9. INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - 10. STOCK OPTIONS AND WARRANTS - Schedule of Option Summary (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - 11. STOCKHOLDERS’ DEFICIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 skvi-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 skvi-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 11 skvi-20221231_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Stock Payable [Member] Retained Earnings [Member] Convertible Notes [Member] Related Party Transaction [Axis] Convertible Notes Payable [Member] Debt Instrument [Axis] Convertible Notes Related Party [Member] Two Officers [Member] Related Party Notes Payable One Nineteen Notes Payable Past Due [Member] Scenario [Axis] Convertible Note One Convertible Note 1 Convertible Note Six Convertible Note 6 Total Comvertible Notes Total Convertible Notes Current [Member] Total Long Term Convertible Notes Current [Member] Derivative Instrument [Axis] Excercise Price One [Member] Option Exercise [Member] Option Cancelled Weighted Average [Member] Excercise Price Two [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Auditor Name Auditor Location Auditor Firm ID Statement of Financial Position [Abstract] ASSETS Current assets Cash Accounts receivable Prepaid expense and other current assets Total current assets Patents and trademarks, net Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities Accounts payable and accrued liabilities Accrued interest payable Loans from related party Loans payable Convertible notes payable Derivative liability Total current liabilities Convertible notes payable related party, net of unamortized discount of $1,228,066 and $1,837,918 respectively Convertible notes payable, net of unamortized debt discount of $101,808 and $152,642, respectively Total liabilities Stockholders' deficit Common stock; $0.001 par value; 200,000,000 shares authorized; 4,539,843 shares issued and outstanding at December 31, 2022 and 2021, respectively Additional paid-in capital Accumulated deficit Total stockholders' deficit Total liabilities and stockholders' deficit Convertible Notes Payable, related party, net of unamortized discount Debt Instrument, Unamortized Discount (Premium), Net Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] Revenues Cost of revenues Gross profit Operating expenses Depreciation and amortization Selling general and administrative Total operating expenses Loss from operations Other income and (expense) Interest expense Loss on change in derivative liability Gain/(loss) on settlement of debt Total other income (expense) Net income (loss) Basic income (loss) per common share Fully diluted income (loss) per common share Basic weighted average common shares outstanding Fully diluted weighted average common shares outstanding Statement [Table] Statement [Line Items] Beginning balance, value Shares, Issued  Derivative liability written off to APIC Stock Issued During Period, Shares, Other  Net loss Ending balance, value Shares, Issued Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Income (loss) Adjustments to reconcile net loss to net cash provided (used) by operating activities: Amortization of debt discount Gain/(loss) on settlement of debt Loss on change in derivative liability Changes in operating assets and liabilities: Decrease (Increase) in prepaid assets Decrease (Increase) in accounts receivable Increase in accounts payable and accrued liabilities Decrease in due from related party Increase in accrued interest Net cash provided by (used in) operating activities Cash flows from investing activities: Purchase of fixed and intangible assets Net cash used in investing activities Cash flows from financing activities: Payments on related party loans Payments on loans payable Payments on convertible notes payable Net cash used in financing activities Net change in cash Cash, beginning of period Cash, end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for interest Cash paid for tax Non-cash investing and financing activities: Beneficial conversion feature on convertible debt Common stock issued on extinguishment of debts Common stock payable on extinguishment of debts Accounting Policies [Abstract] 1. DESCRIPTION OF BUSINESS AND HISTORY 2. BASIS OF PRESENTATION AND GOING CONCERN 3. SUMMARY OF SIGNIFICANT POLICIES Related Party Transactions [Abstract] 4. RELATED PARTY TRANSACTIONS Goodwill and Intangible Assets Disclosure [Abstract] 5. INTANGIBLE AND OTHER ASSETS Debt Disclosure [Abstract] 6. NOTES PAYABLE 7. CONVERTIBLE NOTES PAYABLE Commitments and Contingencies Disclosure [Abstract] 8. COMMITMENTS AND CONTINGENCIES Income Tax Disclosure [Abstract] 9. INCOME TAXES Share-Based Payment Arrangement [Abstract] 10. STOCK OPTIONS AND WARRANTS Equity [Abstract] 11. STOCKHOLDERS’ DEFICIT Subsequent Events [Abstract] 12. SUBSEQUENT EVENTS Description of business History Basis of presentation Going concern Principles of consolidation Use of estimates Cash and cash equivalents Fair Value of financial instruments Revenue recognition Accounts Receivable Intangible assets Income taxes Stock-based compensation Earnings (loss) per share Recently issued accounting pronouncements 4. RELATED PARTY TRANSACTIONS - Schedule of Convertible Notes Payable Related Party 7. CONVERTIBLE NOTES PAYABLE - Schedule of Convertible Notes Payable 9. INCOME TAXES - Deferred Tax Assrts and Liabilities 10. STOCK OPTIONS AND WARRANTS - Schedule of Option Summary Entity Incorporation, Date of Incorporation Net Income (Loss) Attributable to Parent Debt Instrument, Convertible, Carrying Amount of Equity Component Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares Weighted Average Number of Shares, Contingently Issuable Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Convertible Notes Payable, Value Accrued Interest Accrued salaries Accrued vacation Unpaid reimbursements Cash advances Conversion terms Debt instrument, term Debt Instrument, Convertible, Beneficial Conversion Feature Financing Interest Expense Repayments of Notes Payable Convertible Notes Payable Debt Instrument, Unamortized Discount Repayments of Related Party Debt Due to Officers or Stockholders, Current Intangible Assets, Current Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Excluding Capital Leased Assets Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Debt Instrument, Interest Rate, Stated Percentage Additional Liability, Long-Duration Insurance, Current Weighted-Average Discount Rate Original issue discount Debt Instrument, Unamortized Discount, Current Notes Payable Debt Instrument, Increase, Accrued Interest Accrued Salaries, Current Accrued Vacation, Current Common Stock, Terms of Conversion Interest Expense Convertible Notes Payable, Current Convertible Notes Payable, Noncurrent Notes payable, interest rate Notes payable, proceeds Notes payable, term Loans Payable Taxes and Licenses Options granted and assumed, weighted average exercise price [custom:LicenseFeeAgreementTerms] [custom:LicenseRevenues] [custom:LicenseRevenues2] Payments to Acquire Management Contract Rights Cumulative tax net operating losses (in millions) Deferred tax asset (in millions) Valuation allowance (in millions) Current taxes payable Income tax expense Effective Income Tax Rate Reconciliation, Percent Operating Loss Carryforwards Estimated Tax Rate Federal net operating loss carryforwards Offsetting Assets [Table] Offsetting Assets [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Assets, Current Assets Liabilities, Current Liabilities Gross Profit Operating Expenses Other Expenses Stockholders' Equity Attributable to Parent Shares, Issued Net Cash Provided by (Used in) Operating Activities Payments to Acquire Other Productive Assets Net Cash Provided by (Used in) Investing Activities Payments for Loans Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount EX-101.PRE 12 skvi-20221231_pre.xml XBRL PRESENTATION FILE